Download Supplementary references (for website)

Hirschhorn et al., Comprehensive review of association studies
References
1. Lander ES, Schork NJ. Genetic dissection of complex traits (published erratum appears in Science
1994;266(5184):353). Science 1994;265:2037-2048.
2. Chakravarti A. Population genetics---making sense out of sequence. Nat Genet 1999;21:56-60.
3. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-856.
4. Harris H. The principles of human biochemical genetics. Amsterdam: North-Holland Publishing
Company, 1975.
5. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin
JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J,
Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton
L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D,
Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander
ES, Atshuler D. A map of human genome sequence variation containing 1.42 million single
nucleotide polymorphisms. Nature 2001;409:928-933.
6. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized
mechanism characterized by poor anticoagulant response to activated protein C: prediction of a
cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008.
7. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA,
Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated
protein C. Nature 1994;369:64-67.
8. Aparicio C, Dahlback B. Molecular mechanisms of activated protein C resistance. Properties of
factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the
factor V gene. Biochem J 1996;313:467-472.
9. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many
A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic
factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment.
Arterioscler Thromb Vasc Biol 1999;19:511-518.
10. Dilley A, Austin H, Hooper WC, El-Jamil M, Whitsett C, Wenger NK, Benson J, Evatt B.
Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous
thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med
1998;132:452-455.
11. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile
methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J
Hum Genet 1991;48:536-545.
12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M,
Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a
common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
13. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A, Graham IM,
Whitehead AS. Homocysteine and risk of premature coronary heart disease. Evidence for a
common gene mutation. Circulation 1996;94:2154-2158.
14. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Heijer
M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a
common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for
cardiovascular disease. Am J Hum Genet 1996;58:35-41.
1
Hirschhorn et al., Comprehensive review of association studies
15. Bailey LB, Gregory JF, 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other
enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999;129:919922.
16. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP,
Mariman EC, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as
a risk factor for spina bifida. Lancet 1995;346:1070-1071.
17. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, Molloy AM, Weir DG, Shields DC,
Scott JM. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects.
QJM 1995;88:763-766.
18. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J,
Hennekens CH, Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary
interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-1102.
19. Margaglione M, D'Andrea G, d'Addedda M, Giuliani N, Cappucci G, Iannaccone L, Vecchione
G, Grandone E, Brancaccio V, Di Minno G. The methylenetetrahydrofolate reductase TT677
genotype is associated with venous thrombosis independently of the coexistence of the FV
Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998;79:907-911.
20. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G.
Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with
susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999;96:12810-12815.
21. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC,
Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and
risk of myocardial infarction in US physicians. Circulation 1996;94:2410-2416.
22. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile
methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis.
Thromb Haemost 1998;79:254-258.
23. Morrison K, Papapetrou C, Hol FA, Mariman EC, Lynch SA, Burn J, Edwards YH.
Susceptibility to spina bifida; an association study of five candidate genes. Ann Hum Genet
1998;62:379-396.
24. Osuntokun BO, Sahota A, Ogunniyi AO, Gureje O, Baiyewu O, Adeyinka A, Oluwole SO,
Komolafe O, Hall KS, Unverzagt FW, et al. Lack of an association between apolipoprotein E
epsilon 4 and Alzheimer's disease in elderly Nigerians. Ann Neurol 1995;38:463-465.
25. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, PericakVance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association
between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and
Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
26. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B,
Mayeux R. The APOE-epsilon4 allele and the risk of Alzheimer disease among African
Americans, whites, and Hispanics. JAMA 1998;279:751-755.
27. Altshuler D, Kruglyak L, Lander E. Genetic polymorphisms and disease [letter; comment]. N
Engl J Med 1998;338:1626.
28. Freely associating. Nat Genet 1999;22:1-2.
29. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR,
Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES.
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2
diabetes [In Process Citation]. Nat Genet 2000;26:76-80.
2
Hirschhorn et al., Comprehensive review of association studies
30. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001;2:9199.
31. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin
gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52:506516.
32. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification
in association studies. Am J Hum Genet 1999;65:220-228.
33. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55:997-1004.
34. Reich DE, Goldstein DB. Detecting association in a case-control study while correcting for
population stratification. Genet Epidemiol 2001;20:4-16.
35. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured
populations. Am J Hum Genet 2000;67:170-181.
36. Morton NE, Collins A. Tests and estimates of allelic association in complex inheritance. Proc
Natl Acad Sci U S A 1998;95:11389-11393.
37. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W,
Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity,
lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
38. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V.
Pro12Ala substitution in the peroxisome proliferator-activated receptor---gamma2 is not
associated with type 2 diabetes. Diabetes 1999;48:1466-1468.
39. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome
proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun
1999;254:450-453.
40. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA,
Charpentier G, Guy-Grand B, Froguel P, Vaisse C. The Pro115Gln and Pro12Ala PPAR gamma
gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24:391-393.
41. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S,
Ito C, Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to
type 2 diabetes. Biochem Biophys Res Commun 2000;271:212-216.
42. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P. Impact of the
peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids
and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-199.
43. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT,
Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The
peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2
diabetes and trait differences. Diabetes 2001;50:886-890.
44. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K,
Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N,
Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M. The Pro12 -->Ala
substitution in PPAR-gamma is associated with resistance to development of diabetes in the
general population: possible involvement in impairment of insulin secretion in individuals with
type 2 diabetes. Diabetes 2001;50:891-894.
45. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute
lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic
polymorphisms. Blood 1999;93:1496-1501.
3
Hirschhorn et al., Comprehensive review of association studies
46. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. Genetic polymorphism of
CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis
1999;20:1225-1229.
47. Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D. Genetic polymorphisms of Nacetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute
lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2000;9:557-562.
48. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Ikemura K, Kawamoto T.
Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity
cancer. Int J Cancer 1999;83:606-609.
49. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic
polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to
bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641-644.
50. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa HM, Au WW. GSTM1 and GSTT1
genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 1998;22:129-138.
51. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated
with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT:
a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-4875.
52. Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S. Association between CYP17 gene
polymorphism and risk of breast cancer in. Int J Cancer 1999;84:350-353.
53. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase
gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456-463.
54. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length
polymorphism is associated with breast cancer in African-American women. Cancer Res
1995;55:3757-3758.
55. Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O, Kawajiri K.
Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer.
Pharmacogenetics 2000;10:25-33.
56. Zheng W, Xie DW, Jin F, Cheng JR, Dai Q, Wen WQ, Shu XO, Gao YT. Genetic polymorphism
of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev
2000;9:147-150.
57. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W. Populationbased, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer
Inst 2000;92:412-417.
58. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL. Oestrogen receptor (ESR)
polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-670.
59. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Watson M,
Comstock GW, Bell D. Association between glutathione S-transferase M1, P1, and T1 genetic
polymorphisms and development of breast cancer. J Natl Cancer Inst 1998;90:512-518.
60. Lidereau R, Escot C, Theillet C, Champeme MH, Brunet M, Gest J, Callahan R. High frequency
of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer
Inst 1986;77:697-701.
61. Chouchane L, Ahmed SB, Baccouche S, Remadi S. Polymorphism in the tumor necrosis factoralpha promotor region and in the heat shock protein 70 genes associated with malignant tumors.
Cancer 1997;80:1489-1496.
4
Hirschhorn et al., Comprehensive review of association studies
62. Zheng W, Deitz AC, Campbell DR, Wen WQ, Cerhan JR, Sellers TA, Folsom AR, Hein DW. Nacetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast
cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:233-239.
63. Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor
in occupational and smoking related bladder cancer. Hum Mol Genet 1995;4:231-236.
64. Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB. Progesterone
receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.
Cancer Res 2000;60:2348-2350.
65. Becchis M, Frairia R, Ferrera P, Fazzari A, Ondei S, Alfarano A, Coluccia C, Biglia N, Sismondi
P, Fortunati N. The additionally glycosylated variant of human sex hormone-binding globulin
(SHBG) is linked to estrogen-dependence of breast cancer. Breast Cancer Res Treat
1999;54:101-107.
66. Ambrosone CB, Coles BF, Freudenheim JL, Shields PG. Glutathione-S-transferase (GSTM1)
genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants.
J Nutr 1999;129:565S-568S.
67. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman
L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-1316.
68. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of A
vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer
1999;83:723-726.
69. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE.
Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and
CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer 2000;88:2082-2091.
70. Piyathilake CJ, Macaluso M, Johanning GL, Whiteside M, Heimburger DC, Giuliano A.
Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervical
intraepithelial neoplasia. Anticancer Res 2000;20:1751-1757.
71. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM,
Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human
papillomavirus-associated cancer. Nature 1998;393:229-234.
72. Crossen PE, Morrison MJ. Elevated frequency of an ETS-1 restriction fragment polymorphism
in chronic B-cell leukaemia. Hum Genet 1993;91:380-382.
73. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, Messer G. Polymorphism of the
tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br
J Haematol 1997;97:107-112.
74. Yokoyama A, Muramatsu T, Ohmori T, Yokoyama T, Okuyama K, Takahashi H, Hasegawa Y,
Higuchi S, Maruyama K, Shirakura K, Ishii H. Alcohol-related cancers and aldehyde
dehydrogenase-2 in Japanese alcoholics. Carcinogenesis 1998;19:1383-1387.
75. Gryfe R, Di Nicola N, Lal G, Gallinger S, Redston M. Inherited colorectal polyposis and cancer
risk of the APC I1307K polymorphism. Am J Hum Genet 1999;64:378-384.
76. Sivaraman L, Leatham MP, Yee J, Wilkens LR, Lau AF, Le Marchand L. CYP1A1 genetic
polymorphisms and in situ colorectal cancer. Cancer Res 1994;54:3692-3695.
77. Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, Zheng S, Wiencke JK,
Lafuente A. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its
association with the presence of K-ras mutations in tumors. Carcinogenesis 2000;21:1813-1819.
5
Hirschhorn et al., Comprehensive review of association studies
78. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic
polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis
1993;14:1821-1824.
79. Deakin M, Elder J, Hendrickse C, Peckham D, Baldwin D, Pantin C, Wild N, Leopard P, Bell
DA, Jones P, Duncan H, Brannigan K, Alldersea J, Fryer AA, Strange RC. Glutathione Stransferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in
lung, oral, gastric and colorectal cancers. Carcinogenesis 1996;17:881-884.
80. Park KS, Mok JW, Rho SA, Kim JC. Analysis of TNFB and TNFA NcoI RFLP in colorectal
cancer. Mol Cells 1998;8:246-249.
81. Orimo H, Nakajima E, Yamamoto M, Ikejima M, Emi M, Shimada T. Association between
single nucleotide polymorphisms in the hMSH3 gene and sporadic colon cancer with
microsatellite instability. J Hum Genet 2000;45:228-230.
82. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C,
Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1)
increases risk of colorectal cancer. Cancer Res 1995;55:3537-3542.
83. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele
NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis
1998;19:37-41.
84. Abdel-Rahman SZ, Soliman AS, Bondy ML, Omar S, El-Badawy SA, Khaled HM, Seifeldin IA,
Levin B. Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene
XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer
Lett 2000;159:79-86.
85. Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K, Wake N. WAF1 genotype and endometrial
cancer susceptibility. Gynecol Oncol 1999;72:187-192.
86. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Germ line polymorphisms
in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR)
genes and endometrial cancer susceptibility. Carcinogenesis 1997;18:2307-2311.
87. Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, Kanamori Y,
Minaguchi T, Nakamura Y, Tokino T, Kudo R. A single nucleotide polymorphism in the matrix
metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 2000;91:612-615.
88. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Susceptibility to
endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1)
and cytochrome P-450 (CYP1A1) loci. Br J Cancer 1997;75:1385-1388.
89. Katoh T, Nagata N, Kuroda Y, Itoh H, Kawahara A, Kuroki N, Ookuma R, Bell DA. Glutathione
S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric
and colorectal adenocarcinoma. Carcinogenesis 1996;17:1855-1859.
90. Setiawan VW, Zhang ZF, Yu GP, Li YL, Lu ML, Tsai CJ, Cordova D, Wang MR, Guo CH, Yu
SZ, Kurtz RC. GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: a case-control
study in a Chinese population. Cancer Epidemiol Biomarkers Prev 2000;9:73-80.
91. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J,
Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Jr., Rabkin CS.
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature
2000;404:398-402.
92. Shibuta K, Mori M, Haraguchi M, Yoshikawa K, Ueo H, Akiyoshi T. Association between
restriction fragment length polymorphism of the L-myc gene and susceptibility to gastric cancer.
Br J Surg 1998;85:681-684.
6
Hirschhorn et al., Comprehensive review of association studies
93. Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling
A, Black PM, Yates AJ, Eng C. Over-representation of PPARgamma sequence variants in
sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance
modifiers for brain tumour risk in the general population. J Med Genet 2000;37:410-414.
94. Hori H, Kawano T, Endo M, Yuasa Y. Genetic polymorphisms of tobacco- and alcohol-related
metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J Clin
Gastroenterol 1997;25:568-575.
95. Ralhan R, Agarwal S, Mathur M, Wasylyk B, Srivastava A. Association between polymorphism
in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin Cancer
Res 2000;6:2440-2447.
96. Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stern JC, Pike V, Richie JP, Jr., Lazarus
P. CYP1A1 and GSTM1 polymorphisms and oral cancer risk [published erratum appears in
Cancer Epidemiol Biomarkers Prev 1997 Dec;6(12):1108]. Cancer Epidemiol Biomarkers Prev
1997;6:791-797.
97. Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, Jones PW, Hand P, Gilford J,
Farrell WE, Hoban P, Fryer AA, Strange RC. Susceptibility and outcome in oral cancer:
preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6.
Pharmacogenetics 1998;8:433-439.
98. Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF. Susceptibility to esophageal
cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome
P450 2E1. Cancer Epidemiol Biomarkers Prev 1998;7:1013-1018.
99. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M.
Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers
Prev 2000;9:843-847.
100. Trizna Z, Clayman GL, Spitz MR, Briggs KL, Goepfert H. Glutathione s-transferase genotypes
as risk factors for head and neck cancer. Am J Surg 1995;170:499-501.
101. Jahnke V, Strange R, Matthias C, Fryer A. Glutathione S-transferase and cytochrome P450
genotypes as risk factors for laryngeal carcinoma. Eur Arch Otorhinolaryngol Suppl
1997;1:S147-149.
102. Morita S, Yano M, Tsujinaka T, Ogawa A, Taniguchi M, Kaneko K, Shiozaki H, Doki Y, Inoue
M, Monden M. Association between genetic polymorphisms of glutathione S-transferase P1 and
N-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus. Int J
Cancer 1998;79:517-520.
103. Matthias C, Jahnke V, Fryer A, Strange R, Ollier W, Hajeer A. Influence of tumour necrosis
factor microsatellite polymorphisms on susceptibility to head and neck cancer. Acta Otolaryngol
1998;118:284-288.
104. Shibuta K, Inoue H, Sato K, Matsuyama A, Ueo H, Tanaka Y, Mafune K, Barnard GF, Mori M.
L-myc restriction fragment length polymorphism in Japanese patients with esophageal cancer.
Jpn J Cancer Res 2000;91:199-203.
105. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic polymorphism
of N-acetyltransferase-2, glutathione S- transferase-M1, and cytochromes P450IIE1 and
P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51:294-298.
106. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L, Beckman G. p53 polymorphisms and
haplotypes in nasopharyngeal cancer. Hum Hered 1996;46:49-54.
107. Agundez JA, Ledesma MC, Benitez J, Ladero JM, Rodriguez-Lescure A, Diaz-Rubio E, DiazRubio M. CYP2D6 genes and risk of liver cancer. Lancet 1995;345:830-831.
7
Hirschhorn et al., Comprehensive review of association studies
108. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome
P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular
carcinoma. Gastroenterology 1995;109:1266-1273.
109. Wong NA, Rae F, Bathgate A, Smith CA, Harrison DJ. Polymorphisms of the gene for
microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular
carcinoma in a Caucasian population. Toxicol Lett 2000;115:17-22.
110. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. Association
between the p21 codon 31 A1 (arg) allele and lung cancer. Hum Hered 1996;46:221-225.
111. Hamada GS, Sugimura H, Suzuki I, Nagura K, Kiyokawa E, Iwase T, Tanaka M, Takahashi T,
Watanabe S, Kino I, et al. The heme-binding region polymorphism of cytochrome P450IA1
(CypIA1), rather than the RsaI polymorphism of IIE1 (CypIIE1), is associated with lung cancer
in Rio de Janeiro. Cancer Epidemiol Biomarkers Prev 1995;4:63-67.
112. Miyamoto M, Umetsu Y, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Nemoto N, Sato
K, Ariyoshi N, Kamataki T. CYP2A6 gene deletion reduces susceptibility to lung cancer.
Biochem Biophys Res Commun 1999;261:658-660.
113. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R,
Watanabe M. Association between restriction fragment length polymorphism of the human
cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991;82:254256.
114. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and
African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone
oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997;6:87-92.
115. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and
African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone
oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997;6:87-92.
116. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung
cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998;58:5291-5293.
117. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, Albanes D.
Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res
2000;60:6381-6383.
118. Sun GF, Shimojo N, Pi JB, Lee S, Kumagai Y. Gene deficiency of glutathione S-transferase mu
isoform associated with susceptibility to lung cancer in a Chinese population. Cancer Lett
1997;113:169-172.
119. Kelsey KT, Spitz MR, Zuo ZF, Wiencke JK. Polymorphisms in the glutathione S-transferase
class mu and theta genes interact and increase susceptibility to lung cancer in minority
populations (Texas, United States). Cancer Causes Control 1997;8:554-559.
120. Lindstedt BA, Ryberg D, Zienolddiny S, Khan H, Haugen A. Hras1 VNTR alleles as
susceptibility markers for lung cancer: relationship to microsatellite instability in tumors.
Anticancer Res 1999;19:5523-5527.
121. Shimura T, Hagihara M, Takebe K, Munkhbat B, Odaka T, Kato H, Nagamachi Y, Tsuji K. The
study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer
1994;73:1184-1188.
122. Ishida T, Takashima R, Fukayama M, Hamada C, Hippo Y, Fujii T, Moriyama S, Matsuba C,
Nakahori Y, Morita H, Yazaki Y, Kodama T, Nishimura S, Aburatani H. New DNA
polymorphisms of human MMH/OGG1 gene: prevalence of one polymorphism among lungadenocarcinoma patients in Japanese. Int J Cancer 1999;80:18-21.
8
Hirschhorn et al., Comprehensive review of association studies
123. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer
risk. Cancer Res 1997;57:5001-5003.
124. Abdel-Rahman SZ, El-Zein RA, Zwischenberger JB, Au WW. Association of the NAT1*10
genotype with increased chromosome aberrations and higher lung cancer risk in cigarette
smokers. Mutat Res 1998;398:43-54.
125. Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S,
Hirvonen A. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk.
Pharmacogenetics 1998;8:291-298.
126. Hirvonen A, Saarikoski ST, Linnainmaa K, Koskinen K, Husgafvel-Pursiainen K, Mattson K,
Vainio H. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated
pulmonary disorders. J Natl Cancer Inst 1996;88:1853-1856.
127. Sikstrom C, Beckman LE, Eklund A, Beckman L. Transferrin C3 offers protection against
smoking-associated lung cancer? Carcinogenesis 1996;17:1447-1449.
128. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and
CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-1089.
129. Radice P, Pierotti MA, Borrello MG, Illeni MT, Rovini D, Della Porta G. HRAS1 protooncogene polymorphisms in human malignant melanoma: TaqI defined alleles significantly
associated with the disease. Oncogene 1987;2:91-95.
130. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL. The
Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum
Mol Genet 1996;5:1663-1666.
131. Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh
KI. A variant within the DNA repair gene XRCC3 is associated with the development of
melanoma skin cancer. Cancer Res 2000;60:5612-5616.
132. Crossen PE, Morrison MJ, Colls BM. Elevated frequency of a SstI polymorphism of the Ets-1
oncogene in non-Hodgkin's lymphoma patients. Cancer Genet Cytogenet 1995;79:70-73.
133. Nair UJ, Nair J, Mathew B, Bartsch H. Glutathione S-transferase M1 and T1 null genotypes as
risk factors for oral leukoplakia in ethnic Indian betel quid/tobacco chewers. Carcinogenesis
1999;20:743-748.
134. Bartsch H, Rojas M, Nair U, Nair J, Alexandrov K. Genetic cancer susceptibility and DNA
adducts: studies in smokers, tobacco chewers, and coke oven workers. Cancer Detect Prev
1999;23:445-453.
135. Weitzel JN, Ding S, Larson GP, Nelson RA, Goodman A, Grendys EC, Ball HG, Krontiris TG.
The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Res 2000;60:259-261.
136. Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A,
Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA,
Runnebaum IB. Intron variants of the p53 gene are associated with increased risk for ovarian
cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer 1999;81:179183.
137. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens
CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to
prostate cancer [published erratum appears in Proc Natl Acad Sci U S A 1997 Jul
22;94(15):8272]. Proc Natl Acad Sci U S A 1997;94:3320-3323.
138. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of
prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J
Natl Cancer Inst 1997;89:166-170.
9
Hirschhorn et al., Comprehensive review of association studies
139. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated
with CYP17 genotype. Pharmacogenetics 1999;9:635-639.
140. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17
hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-1731.
141. Murata M, Shiraishi T, Fukutome K, Watanabe M, Nagao M, Kubota Y, Ito H, Kawamura J,
Yatani R. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for
prostate cancer in Japan. Jpn J Clin Oncol 1998;28:657-660.
142. Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, Lin DX, Tan W, LynCook BD, Hammons GJ, Kadlubar FF. Human CYP1B1 Leu432Val gene polymorphism: ethnic
distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and
distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761-766.
143. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS.
Association between a CYP3A4 genetic variant and clinical presentation in African-American
prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-905.
144. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein
AJ, Malkowicz SB. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum
Genet 2000;67:1014-1019.
145. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE,
Reichardt JK. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in
African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-978.
146. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate
cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108-4110.
147. Longuemaux S, Delomenie C, Gallou C, Mejean A, Vincent-Viry M, Bouvier R, Droz D,
Krishnamoorthy R, Galteau MM, Junien C, Beroud C, Dupret JM. Candidate genetic modifiers
of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobioticmetabolizing enzymes. Cancer Res 1999;59:2903-2908.
148. Sweeney C, Farrow DC, Schwartz SM, Eaton DL, Checkoway H, Vaughan TL. Glutathione Stransferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control
study. Cancer Epidemiol Biomarkers Prev 2000;9:449-454.
149. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L,
Ricard S, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent
risk factor for myocardial infarction. Nature 1992;359:641-644.
150. Higashi K, Ishikawa T, Ito T, Yonemura A, Shige H, Nakamura H. Association of a genetic
variation in the beta 3-adrenergic receptor gene with coronary heart disease among Japanese.
Biochem Biophys Res Commun 1997;232:728-730.
151. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G,
Kee F, Ducimetiere P, et al. Synergistic effects of angiotensin-converting enzyme and
angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet
1994;344:910-913.
152. Ordovas JM, Schaefer EJ, Salem D, Ward RH, Glueck CJ, Vergani C, Wilson PW,
Karathanasis SK. Apolipoprotein A-I gene polymorphism associated with premature coronary
artery disease and familial hypoalphalipoproteinemia. N Engl J Med 1986;314:671-677.
153. Hegele RA, Huang LS, Herbert PN, Blum CB, Buring JE, Hennekens CH, Breslow JL.
Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction. N Engl J
Med 1986;315:1509-1515.
10
Hirschhorn et al., Comprehensive review of association studies
154. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with
coronary heart disease. Lancet 1992;340:879-880.
155. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, Schmitz G. C(-260)-->T
polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for
myocardial infarction. Circulation 1999;99:3218-3220.
156. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the
NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation
1998;97:135-137.
157. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a
common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost
1998;79:8-13.
158. Arruda VR, Siquiera LH, Chiaparini LC, Coelho OR, Mansur AP, Ramires A, AnnichinoBizzacchi JM. Prevalence of the prothrombin gene variant 20210 G --> A among patients with
myocardial infarction. Cardiovasc Res 1998;37:42-45.
159. Le W, Yu JD, Lu L, Tao R, You B, Cai X, Cao WJ, Huang W, He RM, Zhu DL, Chen Z, Gong
LS. Association of the R485K polymorphism of the factor V gene with poor response to
activated protein C and increased risk of coronary artery disease in the Chinese population [In
Process Citation]. Clin Genet 2000;57:296-303.
160. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C,
Benedetta Donati M. Polymorphisms in the coagulation factor VII gene and the risk of
myocardial infarction. N Engl J Med 1998;338:79-85.
161. Fowkes FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GD. Fibrinogen genotype and
risk of peripheral atherosclerosis. Lancet 1992;339:693-696.
162. Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V.
Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease.
Blood 1998;92:2771-2776.
163. Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is
associated with a decreased risk of myocardial infarction. FASEB J 2000;14:791-796.
164. Yamada S, Akita H, Kanazawa K, Ishida T, Hirata K, Ito K, Kawashima S, Yokoyama M.
T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute
myocardial infarction. Atherosclerosis 2000;150:143-148.
165. Baroni MG, D'Andrea MP, Montali A, Pannitteri G, Barilla F, Campagna F, Mazzei E, Lovari
S, Seccareccia F, Campa PP, Ricci G, Pozzilli P, Urbinati G, Arca M. A common mutation of the
insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Arterioscler Thromb
Vasc Biol 1999;19:2975-2980.
166. Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S, Meyer BJ.
Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of
myocardial infarction: a case-control study. Lancet 1999;353:351-354.
167. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith
G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited
risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-1094.
168. Thorn JA, Chamberlain JC, Alcolado JC, Oka K, Chan L, Stocks J, Galton DJ. Lipoprotein and
hepatic lipase gene variants in coronary atherosclerosis. Atherosclerosis 1990;85:55-60.
169. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, Matsuda Y, Takai E, Iwai C,
Kurogane H, Yoshida Y, Yokoyama M. Stromelysin promoter 5A/6A polymorphism is
associated with acute myocardial infarction. Circulation 1999;99:2717-2719.
11
Hirschhorn et al., Comprehensive review of association studies
170. Ichihara S, Yamada Y, Yokota M. Association of a G994-->T missense mutation in the plasma
platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated
cardiomyopathy in Japanese. Circulation 1998;98:1881-1885.
171. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa H, Harada E,
Masuda T, Koyama W, Saito Y, Miyamoto Y, Ogawa Y, Nakao K. Association of the missense
Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am
Coll Cardiol 1998;31:1506-1510.
172. Rutledge DR, Sun Y, Ross EA. Polymorphisms within the atrial natriuretic peptide gene in
essential hypertension. J Hypertens 1995;13:953-955.
173. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PT, Hofman A, Kluft C,
Grobbee DE. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam
Study. Circulation 1997;95:2623-2627.
174. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a
risk factor for coronary artery disease.
175. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes
(PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet
1998;62:36-44.
176. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161-->T
polymorphism and coronary artery disease. Cardiovasc Res 1999;44:588-594.
177. Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, Schulte KL, Glaser C, Rohde
K, Baumann G, et al. E-selectin polymorphism and atherosclerosis: an association study. Hum
Mol Genet 1994;3:1935-1937.
178. Herrmann SM, Ricard S, Nicaud V, Mallet C, Evans A, Ruidavets JB, Arveiler D, Luc G,
Cambien F. The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele
carriers in patients with myocardial infarction. Hum Mol Genet 1998;7:1277-1284.
179. Ishigami T, Umemura S, Iwamoto T, Tamura K, Hibi K, Yamaguchi S, Nyuui N, Kimura K,
Miyazaki N, Ishii M. Molecular variant of angiotensinogen gene is associated with coronary
atherosclerosis. Circulation 1995;91:951-954.
180. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ,
MacMahon S. Association of angiotensinogen gene T235 variant with increased risk of coronary
heart disease. Lancet 1995;345:1600-1603.
181. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in
basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial
infarction. Proc Natl Acad Sci U S A 1995;92:1851-1855.
182. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G,
Ruidavets JB, Poirier O. Polymorphisms of the transforming growth factor-beta 1 gene in
relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du
Myocarde (ECTIM) Study. Hypertension 1996;28:881-887.
183. Norlund L, Holm J, Zoller B, Ohlin AK. A common thrombomodulin amino acid dimorphism
is associated with myocardial infarction. Thromb Haemost 1997;77:248-251.
184. Ye L, Miki T, Nakura J, Oshima J, Kamino K, Rakugi H, Ikegami H, Higaki J, Edland SD,
Martin GM, Ogihara T. Association of a polymorphic variant of the Werner helicase gene with
myocardial infarction in a Japanese population [published erratum appears in Am J Med Genet
1997 May 2;70(1):103]. Am J Med Genet 1997;68:494-498.
185. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a
common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999;93:906-908.
12
Hirschhorn et al., Comprehensive review of association studies
186. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'untranslated region of the prothrombin gene is associated with elevated plasma prothrombin
levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
187. Arnaud E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, Arveiler D, Luc G,
Ruidavets JB, Emmerich J, Fiessinger JN, Aiach M. Polymorphisms in the 5' regulatory region
of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the
ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris
Thrombosis case-control Study. Arterioscler Thromb Vasc Biol 2000;20:892-898.
188. Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, Phillips DJ, Whitsett C,
Rawlins P, Evatt BL. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in AfricanAmerican adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb
Res 2000;99:223-230.
189. Murata M, Nakagawa M, Takahashi S. Molecular variant of the human
paraoxonase/arylesterase gene is associated with central retinal vein occlusion in the Japanese
population. Ophthalmologica 1998;212:257-259.
190. Harn HJ, Chang CY, Ho LI, Liu CA, Jeng JR, Lin FG, Jent W. Evidence that polymorphism of
the angiotensin I converting enzyme gene may be related to idiopathic dilated cardiomyopathy in
the Chinese population. Biochem Mol Biol Int 1995;35:1175-1181.
191. Charron P, Tesson F, Poirier O, Nicaud V, Peuchmaurd M, Tiret L, Cambien F, Amouyel P,
Dubourg O, Bouhour J, Millaire A, Juilliere Y, Bareiss P, Andre-Fouet X, Pouillart F, Arveiler
D, Ferrieres J, Dorent R, Roizes G, Schwartz K, Desnos M, Komajda M. Identification of a
genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the
endothelin receptor type A gene. CARDIGENE group. Eur Heart J 1999;20:1587-1591.
192. Hiroi S, Harada H, Nishi H, Satoh M, Nagai R, Kimura A. Polymorphisms in the SOD2 and
HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in
Japanese. Biochem Biophys Res Commun 1999;261:332-339.
193. Zee RY, Lou YK, Griffiths LR, Morris BJ. Association of a polymorphism of the angiotensin Iconverting enzyme gene with essential hypertension. Biochem Biophys Res Commun
1992;184:9-15.
194. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M, Nembri P, Amar K, Gatti
M, Macciardi F, et al. Association of the alpha-adducin locus with essential hypertension.
Hypertension 1995;25:320-326.
195. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F,
Corvol P, Soubrier F. Angiotensin II type 1 receptor gene polymorphisms in human essential
hypertension. Hypertension 1994;24:63-69.
196. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L,
Soubrier F. Structural analysis and evaluation of the aldosterone synthase gene in hypertension.
Hypertension 1998;32:198-204.
197. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S,
Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T,
Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H,
Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential
hypertension. Hypertension 1998;32:3-8.
198. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a variable number of tandem
repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in
Japanese. Am J Hypertens 1998;11:125-128.
13
Hirschhorn et al., Comprehensive review of association studies
199. Sato M, Soma M, Nakayama T, Kanmatsuse K. Dopamine D1 receptor gene polymorphism is
associated with essential hypertension. Hypertension 2000;36:183-186.
200. Chiang FT, Chiu KC, Tseng YZ, Lee KC, Chuang LM. Nucleotide(-258) G-to-A transition
variant of the liver glucokinase gene is associated with essential hypertension. Am J Hypertens
1997;10:1049-1052.
201. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, Lloyd DD, Brown MJ.
Association of the G(s)alpha gene with essential hypertension and response to beta-blockade.
Hypertension 1999;34:8-14.
202. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann
HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with
hypertension. Nat Genet 1998;18:45-48.
203. Schalin-Jantti C, Nikula-Ijas P, Huang X, Lehto M, Knudsen P, Syvanne M, Lehtovirta MT,
Tikkanen T, Tikkanen I, Groop LC. Polymorphism of the glycogen synthase gene in
hypertensive and normotensive subjects. Hypertension 1996;27:67-71.
204. Watson B, Jr., Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic
association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites
with essential hypertension in blacks. Hypertension 1996;28:478-482.
205. Ying LH, Zee RY, Griffiths LR, Morris BJ. Association of a RFLP for the insulin receptor
gene, but not insulin, with essential hypertension. Biochem Biophys Res Commun 1991;181:486492.
206. Nakata Y, Katsuya T, Takami S, Sato N, Fu Y, Ishikawa K, Takiuchi S, Rakugi H, Miki T,
Higaki J, Ogihara T. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood
pressure and cerebrovascular disease. Am J Hypertens 1998;11:1019-1023.
207. Frossard PM, Lestringant GG, Malloy MJ, Kane JP. Human renin gene BglI dimorphism
associated with hypertension in two independent populations. Clin Genet 1999;56:428-433.
208. Iwai N, Ohmichi N, Hanai K, Nakamura Y, Kinoshita M. Human SA gene locus as a candidate
locus for essential hypertension. Hypertension 1994;23:375-380.
209. Baker EH, Dong YB, Sagnella GA, Rothwell M, Onipinla AK, Markandu ND, Cappuccio FP,
Cook DG, Persu A, Corvol P, Jeunemaitre X, Carter ND, MacGregor GA. Association of
hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people
resident in London. Lancet 1998;351:1388-1392.
210. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC,
Hopkins PN, Williams RR, Lalouel JM, et al. Molecular basis of human hypertension: role of
angiotensinogen. Cell 1992;71:169-180.
211. Sharma P, Hingorani A, Jia H, Ashby M, Hopper R, Clayton D, Brown MJ. Positive association
of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension
1998;32:676-682.
212. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. The
Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive
heart failure. J Clin Invest 1998;102:1534-1539.
213. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW. Common variant in
AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation
1999;99:1422-1425.
214. Ando I, Kukita A, Soma G, Hino H. A large number of tandem repeats in the polymorphic
epithelial mucin gene is associated with severe acne. J Dermatol 1998;25:150-152.
14
Hirschhorn et al., Comprehensive review of association studies
215. Westphal GA, Reich K, Schulz TG, Neumann C, Hallier E, Schnuch A. N-acetyltransferase 1
and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Br J Dermatol
2000;142:1121-1127.
216. Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai M, Sasaki S, Enomoto T,
Hashimoto T, Furuyama J, Hopkin JM, Morimoto K. Association between genetic variants of
mast-cell chymase and eczema [published erratum appears in Lancet 1997 Jan 4;349(9044):64].
Lancet 1996;348:581-583.
217. Wyatt RJ, Wang C, Hudson EC, Jones RM, Noah PW, Rosenberg EW. Complement
phenotypes in patients with psoriasis. Hum Hered 1989;39:327-332.
218. Allen MH, Veal C, Faassen A, Powis SH, Vaughan RW, Trembath RC, Barker JN. A non-HLA
gene within the MHC in psoriasis [letter]. Lancet 1999;353:1589-1590.
219. Vasku V, Vasku A, Izakovicova Holla L, Tschoplova S, Kankova K, Benakova N, Semradova
V. Polymorphisms in inflammation genes (angiotensinogen, TAP1 and TNF-beta) in psoriasis.
Arch Dermatol Res 2000;292:531-534.
220. Gonzalez S, Martinez-Borra J, Del Rio JS, Santos-Juanes J, Lopez-Vazquez A, Blanco-Gelaz
M, Lopez-Larrea C. The OTF3 gene polymorphism confers susceptibility to psoriasis
independent of the association of HLA-Cw*0602. J Invest Dermatol 2000;115:824-828.
221. Hohler T, Weinmann A, Schneider PM, Rittner C, Schopf RE, Knop J, Hasenclever P, Meyer
zum Buschenfelde KH, Marker-Hermann E. TAP-polymorphisms in juvenile onset psoriasis and
psoriatic arthritis. Hum Immunol 1996;51:49-54.
222. Arias AI, Giles B, Eiermann TH, Sterry W, Pandey JP. Tumor necrosis factor-alpha gene
polymorphism in psoriasis. Exp Clin Immunogenet 1997;14:118-122.
223. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, Meyer zum Buschenfelde
KH, Marker-Hermann E. A TNF-alpha promoter polymorphism is associated with juvenile onset
psoriasis and psoriatic arthritis. J Invest Dermatol 1997;109:562-565.
224. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated
with psoriasis. J Invest Dermatol 1999;112:113-116.
225. Kemp EH, Ajjan RA, Husebye ES, Peterson P, Uibo R, Imrie H, Pearce SH, Watson PF,
Weetman AP. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated
with autoimmune Addison's disease in English patients. Clin Endocrinol (Oxf) 1998;49:609-613.
226. Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S. Increased risk for
gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor II
restriction fragment length polymorphisms. Genet Epidemiol 1989;6:559-569.
227. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism
associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995;80:4145.
228. Siegmund T, Usadel KH, Donner H, Braun J, Walfish PG, Badenhoop K. Interferon-gamma
gene microsatellite polymorphisms in patients with Graves' disease. Thyroid 1998;8:1013-1017.
229. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI. Cytokine gene
polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 2000;85:1984-1988.
230. Rau H, Nicolay A, Usadel KH, Finke R, Donner H, Walfish PG, Badenhoop K. Polymorphisms
of TAP1 and TAP2 genes in Graves' disease. Tissue Antigens 1997;49:16-22.
231. Tassi V, Scarnecchia L, Di Cerbo A, Pirro MT, Di Paola R, Liuzzi A, Torlontano M, Zingrillo
M, D'Aloiso L, De Filippis V. A thyroid hormone receptor beta gene polymorphism associated
with Graves' disease. J Mol Endocrinol 1995;15:267-272.
15
Hirschhorn et al., Comprehensive review of association studies
232. Sale MM, Akamizu T, Howard TD, Yokota T, Nakao K, Mori T, Iwasaki H, Rich SS, JenningsGee JE, Yamada M, Bowden DW. Association of autoimmune thyroid disease with a
microsatellite marker for the thyrotropin receptor gene and CTLA-4 in a Japanese population.
Proc Assoc Am Physicians 1997;109:453-461.
233. Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in
Japanese patients with Graves' disease. Thyroid 2000;10:375-380.
234. Carling T, Kindmark A, Hellman P, Lundgren E, Ljunghall S, Rastad J, Akerstrom G, Melhus
H. Vitamin D receptor genotypes in primary hyperparathyroidism. Nat Med 1995;1:1309-1311.
235. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the
androgen receptor are associated with reduced trans-activation, impaired sperm production, and
male infertility. J Clin Endocrinol Metab 1997;82:3777-3782.
236. Ramanujam LN, Liao WX, Roy AC, Ng SC. Association of molecular variants of luteinizing
hormone with male infertility. Hum Reprod 2000;15:925-928.
237. Hani EH, Clement K, Velho G, Vionnet N, Hager J, Philippi A, Dina C, Inoue H, Permutt MA,
Basdevant A, North M, Demenais F, Guy-Grand B, Froguel P. Genetic studies of the
sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians.
Diabetes 1997;46:688-694.
238. Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L, Arner P. Human
beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with
altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997;100:3005-3013.
239. Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, Walston J, Yoshinaga
H, Kosaka K, Yamada N, et al. A mutation in the beta 3-adrenergic receptor gene is associated
with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun
1995;215:555-560.
240. Rajput-Williams J, Knott TJ, Wallis SC, Sweetnam P, Yarnell J, Cox N, Bell GI, Miller NE,
Scott J. Variation of apolipoprotein-B gene is associated with obesity, high blood cholesterol
levels, and increased risk of coronary heart disease. Lancet 1988;2:1442-1446.
241. Vijayaraghavan S, Hitman GA, Kopelman PG. Apolipoprotein-D polymorphism: a genetic
marker for obesity and hyperinsulinemia. J Clin Endocrinol Metab 1994;79:568-570.
242. Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber C, Crookes R, Du PHA,
Epplen JT, Fridey J, Freedman BI, Muller N, Stolke D, Sharma AM, Al Moutaery K, GrosseWilde H, Buerbaum B, Ehrlich T, Ahmad HR, Horsthemke B, Du Toit ED, Tiilikainen A, Ge J,
Wang Y, Rosskopf D, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T
allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J
Am Soc Nephrol 1999;10:1921-1930.
243. Rutherford S, Nyholt DR, Curtain RP, Quinlan SR, Gaffney PT, Morris BJ, Griffiths LR.
Association of a low density lipoprotein receptor microsatellite variant with obesity. Int J Obes
Relat Metab Disord 1997;21:1032-1037.
244. Li WD, Reed DR, Lee JH, Xu W, Kilker RL, Sodam BR, Price RA. Sequence variants in the 5'
flanking region of the leptin gene are associated with obesity in women. Ann Hum Genet
1999;63:227-234.
245. Klannemark M, Orho M, Langin D, Laurell H, Holm C, Reynisdottir S, Arner P, Groop L. The
putative role of the hormone-sensitive lipase gene in the pathogenesis of Type II diabetes
mellitus and abdominal obesity. Diabetologia 1998;41:1516-1522.
246. Oeffner F, Bornholdt D, Ziegler A, Hinney A, Gorg T, Gerber G, Goldschmidt HP, Siegfried
W, Wright A, Hebebrand J, Grzeschik KH. Significant association between a silent
16
Hirschhorn et al., Comprehensive review of association studies
polymorphism in the neuromedin B gene and body weight in German children and adolescents.
Acta Diabetol 2000;37:93-101.
247. Jenkinson CP, Cray K, Walder K, Herzog H, Hanson, Ravussin E. Novel polymorphisms in the
neuropeptide-Y Y5 receptor associated with obesity in Pima Indians. Int J Obes Relat Metab
Disord 2000;24:580-584.
248. Li WD, Lee JH, Price RA. The peroxisome proliferator-activated receptor gamma 2 Pro12Ala
mutation is associated with early onset extreme obesity and reduced fasting glucose. Mol Genet
Metab 2000;70:159-161.
249. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, Ruidavets JB, Luc G, Bara
L, Parra HJ, Poirier O, Cambien F. Polymorphisms of the tumour necrosis factor-alpha gene,
coronary heart disease and obesity. Eur J Clin Invest 1998;28:59-66.
250. Grant SF, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and
osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene.
Nat Genet 1996;14:203-205.
251. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 7138delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic
women than in normal women and is associated with very low bone mass in osteoporotic women
and increased bone turnover in both osteoporotic and normal women. Bone 1997;20:289-294.
252. Yanagi H, Tomura S, Kawanami K, Hosokawa M, Tanaka M, Kobayashi K, Tsuchiya S,
Amagai H, Hayashi K, Hamaguchi H. Vitamin D receptor gene polymorphisms are associated
with osteoporosis in Japanese women [letter; comment]. J Clin Endocrinol Metab 1996;81:41794181.
253. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M,
Franks S, Williamson R. Association of the steroid synthesis gene CYP11a with polycystic ovary
syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.
254. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R.
Polycystic ovaries and premature male pattern baldness are associated with one allele of the
steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-1876.
255. Tong Y, Liao WX, Roy AC, Ng SC. Association of AccI polymorphism in the folliclestimulating hormone beta gene with polycystic ovary syndrome. Fertil Steril 2000;74:12331236.
256. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF 3rd,
Spielman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest
evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999;96:8573-8578.
257. Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, Batty S, Conway GS, White
D, Todd JA, Franks S, Williamson R. Linkage and association of insulin gene VNTR regulatory
polymorphism with polycystic ovary syndrome. Lancet 1997;349:986-990.
258. Ramanujam LN, Liao WX, Roy AC, Loganath A, Goh HH, Ng SC. Association of molecular
variants of luteinizing hormone with menstrual disorders. Clin Endocrinol (Oxf) 1999;51:243246.
259. Miyake H, Nagashima K, Onigata K, Nagashima T, Takano Y, Morikawa A. Allelic variations
of the D2 dopamine receptor gene in children with idiopathic short stature. J Hum Genet
1999;44:26-29.
260. Minamitani K, Takahashi Y, Minagawa M, Yasuda T, Niimi H. Difference in height associated
with a translation start site polymorphism in the vitamin D receptor gene. Pediatr Res
1998;44:628-632.
17
Hirschhorn et al., Comprehensive review of association studies
261. Tao C, Yu T, Garnett S, Briody J, Knight J, Woodhead H, Cowell CT. Vitamin D receptor
alleles predict growth and bone density in girls. Arch Dis Child 1998;79:488-493; discussion
493-484.
262. Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, Nishiyama S, Matsuda
I. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical
evaluation. Hum Genet 1998;103:435-440.
263. Lhotta K, Auinger M, Kronenberg F, Irsigler K, Konig P. Polymorphism of complement C4
and susceptibility to IDDM and microvascular complications. Diabetes Care 1996;19:53-55.
264. Szalai C, Csaszar A, Czinner A, Szabo T, Panczel P, Madacsy L, Falus A. Chemokine receptor
CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus. Pediatr
Res 1999;46:82-84.
265. Ghabanbasani MZ, Buyse I, Legius E, Decorte R, Marynen P, Bouillon R, Cassiman JJ.
Possible association of CD3 and CD4 polymorphisms with insulin-dependent diabetes mellitus
(IDDM). Clin Exp Immunol 1994;97:517-521.
266. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, Larrad MT,
Rios MS, Chow CC, Cockram CS, Jacobs K, Mijovic C, Bain SC, Barnett AH, Vandewalle CL,
Schuit F, Gorus FK, Tosi R, Pozzilli P, Todd JA. The CTLA-4 gene region of chromosome 2q33
is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet
1996;5:1075-1080.
267. Rowe RE, Wapelhorst B, Bell GI, Risch N, Spielman RS, Concannon P. Linkage and
association between insulin-dependent diabetes mellitus (IDDM) susceptibility and markers near
the glucokinase gene on chromosome 7. Nat Genet 1995;10:240-242.
268. Nishimura M, Obayashi H, Maruya E, Ohta M, Tegoshi H, Fukui M, Hasegawa G, Shigeta H,
Kitagawa Y, Nakano K, Saji H, Nakamura N. Association between type 1 diabetes age-at-onset
and intercellular adhesion molecule-1 (ICAM-1) gene polymorphism. Hum Immunol
2000;61:507-510.
269. Kristiansen OP, Nolsoe RL, Holst H, Reker S, Larsen ZM, Johannesen J, Nerup J, Pociot F,
Mandrup-Poulsen T. The intercellular adhesion molecule-1 K469E polymorphism in type 1
diabetes. Immunogenetics 2000;52:107-111.
270. Awata T, Matsumoto C, Urakami T, Hagura R, Amemiya S, Kanazawa Y. Association of
polymorphism in the interferon gamma gene with IDDM. Diabetologia 1994;37:1159-1162.
271. Veijola R, Knip M, Puukka R, Reijonen H, Cox DW, Ilonen J. The immunoglobulin heavychain variable region in insulin-dependent diabetes mellitus: affected-sib-pair analysis and
association studies. Am J Hum Genet 1996;59:462-470.
272. Jahromi MM, Millward BA, Demaine AG. A polymorphism in the promoter region of the gene
for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus. J Interferon
Cytokine Res 2000;20:885-888.
273. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated
with insulin-dependent diabetes mellitus. Diabetes 1984;33:176-183.
274. Pociot F, Molvig J, Wogensen L, Worsaae H, Dalboge H, Baek L, Nerup J. A tumour necrosis
factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes
mellitus. Scand J Immunol 1991;33:37-49.
275. Iwata I, Nagafuchi S, Nakashima H, Kondo S, Koga T, Yokogawa Y, Akashi T, Shibuya T,
Umeno Y, Okeda T, Shibata S, Kono S, Yasunami M, Ohkubo H, Niho Y. Association of
polymorphism in the NeuroD/BETA2 gene with type 1 diabetes in the Japanese. Diabetes
1999;48:416-419.
18
Hirschhorn et al., Comprehensive review of association studies
276. Deng GY, Muir A, Maclaren NK, She JX. Association of LMP2 and LMP7 genes within the
major histocompatibility complex with insulin-dependent diabetes mellitus: population and
family studies. Am J Hum Genet 1995;56:528-534.
277. McDermott MF, Ramachandran A, Ogunkolade BW, Aganna E, Curtis D, Boucher BJ,
Snehalatha C, Hitman GA. Allelic variation in the vitamin D receptor influences susceptibility to
IDDM in Indian Asians. Diabetologia 1997;40:971-975.
278. Awata T, Inoue K, Kurihara S, Ohkubo T, Inoue I, Abe T, Takino H, Kanazawa Y, Katayama
S. Missense variations of the gene responsible for Wolfram syndrome (WFS1/wolframin) in
Japanese: possible contribution of the Arg456His mutation to type 1 diabetes as a
nonautoimmune genetic basis. Biochem Biophys Res Commun 2000;268:612-616.
279. Inoue H, Ferrer J, Welling CM, Elbein SC, Hoffman M, Mayorga R, Warren-Perry M, Zhang
Y, Millns H, Turner R, Province M, Bryan J, Permutt MA, Aguilar-Bryan L. Sequence variants
in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes
1996;45:825-831.
280. Hsieh MC, Lin SR, Hsieh TJ, Hsu CH, Chen HC, Shin SJ, Tsai JH. Increased frequency of
angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol
Dial Transplant 2000;15:1008-1013.
281. Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of
polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and
diabetes mellitus. Diabetologia 1999;42:98-101.
282. Yamada K, Ishiyama-Shigemoto S, Ichikawa F, Yuan X, Koyanagi A, Koyama W, Nonaka K.
Polymorphism in the 5'-leader cistron of the beta2-adrenergic receptor gene associated with
obesity and type 2 diabetes. J Clin Endocrinol Metab 1999;84:1754-1757.
283. Ghabanbasani MZ, Spaepen M, Buyse I, Legius E, Decorte R, Bex M, Marynen P, Bouillon R,
Cassiman JJ. Increased and decreased relative risk for non-insulin-dependent diabetes mellitus
conferred by HLA class II and by CD4 alleles. Clin Genet 1995;47:225-230.
284. Ristow M, Giannakidou E, Hebinck J, Busch K, Vorgerd M, Kotzka J, Knebel B, MuellerBerghaus J, Epplen C, Pfeiffer A, Kahn CR, Doria A, Krone W, Mueller-Wieland D. An
association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin
(Friedreich's ataxia) gene. Diabetes 1998;47:851-854.
285. Gough SC, Saker PJ, Pritchard LE, Merriman TR, Merriman ME, Rowe BR, Kumar S, Aitman
T, Barnett AH, Turner RC, et al. Mutation of the glucagon receptor gene and diabetes mellitus in
the UK: association or founder effect? Hum Mol Genet 1995;4:1609-1612.
286. Hager J, Hansen L, Vaisse C, Vionnet N, Philippi A, Poller W, Velho G, Carcassi C, Contu L,
Julier C, et al. A missense mutation in the glucagon receptor gene is associated with non-insulindependent diabetes mellitus. Nat Genet 1995;9:299-304.
287. Chiu KC, Province MA, Permutt MA. Glucokinase gene is genetic marker for NIDDM in
American blacks. Diabetes 1992;41:843-849.
288. Chiu KC, Province MA, Dowse GK, Zimmet PZ, Wagner G, Serjeantson S, Permutt MA. A
genetic marker at the glucokinase gene locus for type 2 (non-insulin-dependent) diabetes mellitus
in Mauritian Creoles. Diabetologia 1992;35:632-638.
289. Groop LC, Kankuri M, Schalin-Jantti C, Ekstrand A, Nikula-Ijas P, Widen E, Kuismanen E,
Eriksson J, Franssila-Kallunki A, Saloranta C, et al. Association between polymorphism of the
glycogen synthase gene and non-insulin-dependent diabetes mellitus [published erratum appears
in N Engl J Med 1993 Apr 15;328(15):1136]. N Engl J Med 1993;328:10-14.
19
Hirschhorn et al., Comprehensive review of association studies
290. Fernandez-Real JM, Vendrell J, Baiget M, Gimferrer E, Ricart W. C282Y and H63D mutations
of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care 1999;22:525-526.
291. Hitman GA, Jowett NI, Williams LG, Humphries S, Winter RM, Galton DJ. Polymorphisms in
the 5'-flanking region of the insulin gene and non-insulin-dependent diabetes. Clin Sci (Colch)
1984;66:383-388.
292. Galton DJ, Trembath RC. Genetic variants of the insulin receptor in type II (non-insulin
dependent) diabetes mellitus. Biomed Biochim Acta 1988;47:323-327.
293. McClain DA, Henry RR, Ullrich A, Olefsky JM. Restriction-fragment-length polymorphism in
insulin-receptor gene and insulin resistance in NIDDM. Diabetes 1988;37:1071-1075.
294. Hani EH, Stoffers DA, Chevre JC, Durand E, Stanojevic V, Dina C, Habener JF, Froguel P.
Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes
mellitus. J Clin Invest 1999;104:R41-48.
295. Sigal RJ, Doria A, Warram JH, Krolewski AS. Codon 972 polymorphism in the insulin receptor
substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol
Metab 1996;81:1657-1659.
296. Hani EH, Boutin P, Durand E, Inoue H, Permutt MA, Velho G, Froguel P. Missense mutations
in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a metaanalysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians.
Diabetologia 1998;41:1511-1515.
297. Yoshida H, Ohagi S, Sanke T, Furuta H, Furuta M, Nanjo K. Association of the prohormone
convertase 2 gene (PCSK2) on chromosome 20 with NIDDM in Japanese subjects. Diabetes
1995;44:389-393.
298. Xia J, Scherer SW, Cohen PT, Majer M, Xi T, Norman RA, Knowler WC, Bogardus C,
Prochazka M. A common variant in PPP1R3 associated with insulin resistance and type 2
diabetes. Diabetes 1998;47:1519-1524.
299. Doria A, Caldwell JS, Ji L, Reynet C, Rich SS, Weremowicz S, Morton CC, Warram JH, Kahn
CR, Krolewski AS. Trinucleotide repeats at the rad locus. Allele distributions in NIDDM and
mapping to a 3-cM region on chromosome 16q. Diabetes 1995;44:243-247.
300. Li SR, Baroni MG, Oelbaum RS, Stock J, Galton DJ. Association of genetic variant of the
glucose transporter with non-insulin-dependent diabetes mellitus. Lancet 1988;2:368-370.
301. Alcolado JC, Baroni MG, Li SR. Association between a restriction fragment length
polymorphism at the liver/islet cell (GluT 2) glucose transporter and familial type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1991;34:734-736.
302. Rissanen J, Wang H, Miettinen R, Karkkainen P, Kekalainen P, Mykkanen L, Kuusisto J,
Karhapaa P, Niskanen L, Uusitupa M, Laakso M. Variants in the hepatocyte nuclear factor1alpha and -4alpha genes in Finnish and Chinese subjects with late-onset type 2 diabetes.
Diabetes Care 2000;23:1533-1538.
303. Meirhaeghe A, Amouyel P, Helbecque N, Cottel D, Otabe S, Froguel P, Vasseur F. An
uncoupling protein 3 gene polymorphism associated with a lower risk of developing Type II
diabetes and with atherogenic lipid profile in a French cohort. Diabetologia 2000;43:1424-1428.
304. Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S.
CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut
1998;43:187-189.
305. McManus R, Moloney M, Borton M, Finch A, Chuan YT, Lawlor E, Weir DG, Kelleher D.
Association of celiac disease with microsatellite polymorphisms close to the tumor necrosis
factor genes. Hum Immunol 1996;45:24-31.
20
Hirschhorn et al., Comprehensive review of association studies
306. Han T, Jiang Z, Suo G, Zhang S. Apolipoprotein B-100 gene Xba I polymorphism and
cholesterol gallstone disease. Clin Genet 2000;57:304-308.
307. Juvonen T, Savolainen MJ, Kairaluoma MI, Lajunen LH, Humphries SE, Kesaniemi YA.
Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients
with gallbladder disease. J Lipid Res 1995;36:804-812.
308. Bachvarov DR, Landry M, Houle S, Pare P, Marceau F. Altered frequency of a promoter
polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease.
Gastroenterology 1998;115:1045-1048.
309. Over HH, Ulgen S, Tuglular T, Tezel A, Avsar E, Geyik G, Basgul S, Sayhan N, Ulusoy N,
Kalayci C, Tozun N. Thrombophilia and inflammatory bowel disease: does factor V mutation
have a role? Eur J Gastroenterol Hepatol 1998;10:827-829.
310. Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahon R, Whorwell PJ, Sinnott PJ,
Hutchinson IV. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens
1999;54:386-390.
311. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, Holdsworth
CD, Duff GW. Novel genetic association between ulcerative colitis and the anti-inflammatory
cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-642.
312. Pokorny RM, Hofmeister A, Galandiuk S, Dietz AB, Cohen ND, Neibergs HL. Crohn's disease
and ulcerative colitis are associated with the DNA repair gene MLH1. Ann Surg 1997;225:718723; discussion 723-715.
313. Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, Weir DG. Increased
prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory
bowel disease, and its clinical implications. Gut 1999;45:389-394.
314. Kyo K, Parkes M, Takei Y, Nishimori H, Vyas P, Satsangi J, Simmons J, Nagawa H, Baba S,
Jewell D, Muto T, Lathrop GM, Nakamura Y. Association of ulcerative colitis with rare VNTR
alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet 1999;8:307-311.
315. Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG,
Pena AS. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in
patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996;103:391-396.
316. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism:
association with Crohn's disease susceptibility. Gut 2000;47:211-214.
317. Smithies AM, Sargen K, Demaine AG, Kingsnorth AN. Investigation of the interleukin 1 gene
cluster and its association with acute pancreatitis. Pancreas 2000;20:234-240.
318. Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF. CTLA-4 gene
polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538-541.
319. Halmos B, Szalay F, Cserniczky T, Nemesanszky E, Lakatos P, Barlage S, Schmitz G, Romics
L, Csaszar A. Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype
polymorphism in a Hungarian population. Dig Dis Sci 2000;45:1091-1095.
320. Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, McKeigue PM,
Kwiatkowski D, Greenwood BM, Snow RW, Hill AV, Scott J. Malaria susceptibility and CD36
mutation. Nature 2000;405:1015-1016.
321. Fernandez-Reyes D, Craig AG, Kyes SA, Peshu N, Snow RW, Berendt AR, Marsh K, Newbold
CI. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1
predisposing to cerebral malaria in Kenya. Hum Mol Genet 1997;6:1357-1360.
21
Hirschhorn et al., Comprehensive review of association studies
322. Burgner D, Xu W, Rockett K, Gravenor M, Charles IG, Hill AV, Kwiatkowski D. Inducible
nitric oxide synthase polymorphism and fatal cerebral malaria [letter]. Lancet 1998;352:11931194.
323. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNFalpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508510.
324. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien
TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW,
O'Brien SJ. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and
disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS
Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City
Cohort (SFCC), ALIVE Study. Science 1997;277:959-965.
325. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ,
Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo
C, Detels R, O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a
deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study,
Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City
Cohort, ALIVE Study [published erratum appears in Science 1996 Nov 15;274(5290):1069].
Science 1996;273:1856-1862.
326. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie
C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T,
Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor
gene. Nature 1996;382:722-725.
327. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF,
McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C. Rapid progression to AIDS
in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science
2000;287:2274-2277.
328. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, Svejgaard A.
Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of
mannose-binding lectin. Lancet 1997;349:236-240.
329. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE,
O'Connell P, Tryon V, Clark RA, Dolan MJ, Ahuja SK. Genealogy of the CCR5 locus and
chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat
Med 1998;4:786-793.
330. Marquet S, Sanchez FO, Arias M, Rodriguez J, Paris SC, Skamene E, Schurr E, Garcia LF.
Variants of the human NRAMP1 gene and altered human immunodeficiency virus infection
susceptibility. J Infect Dis 1999;180:1521-1525.
331. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit J, Blackwell JM.
Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J
Exp Med 1995;182:1259-1264.
332. Roy S, McGuire W, Mascie-Taylor CG, Saha B, Hazra SK, Hill AV, Kwiatkowski D. Tumor
necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis
1997;176:530-532.
333. Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CG, Hill AV. Association of vitamin D
receptor genotype with leprosy type. J Infect Dis 1999;179:187-191.
22
Hirschhorn et al., Comprehensive review of association studies
334. Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JG, Kuijper EJ.
Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity
of meningococcal disease. Clin Infect Dis 1998;27:746-750.
335. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G
promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of
meningococcal disease. Meningococcal Research Group [In Process Citation]. Lancet
1999;354:556-560.
336. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene
promoter region may be associated with death from meningococcal disease. J Infect Dis
1996;174:878-880.
337. Ramsay CE, Hayden CM, Tiller KJ, Burton PR, Hagel I, Palenque M, Lynch NR, Goldblatt J,
LeSouef PN. Association of polymorphisms in the beta2-adrenoreceptor gene with higher levels
of parasitic infection. Hum Genet 1999;104:269-274.
338. Martin J, Calzada JE, Nieto A. Inducible nitric oxide synthase (NOS2) gene polymorphism and
parasitic diseases [letter; comment]. Lancet 1999;353:72.
339. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis
with the interleukin 8 gene region in UK families. Thorax 2000;55:1023-1027.
340. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the
interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to
susceptibility to severe sepsis. Crit Care Med 1999;27:1330-1334.
341. Mozzato-Chamay N, Mahdi OS, Jallow O, Mabey DC, Bailey RL, Conway DJ. Polymorphisms
in candidate genes and risk of scarring trachoma in a Chlamydia trachomatis--endemic
population. J Infect Dis 2000;182:1545-1548.
342. Conway DJ, Holland MJ, Bailey RL, Campbell AE, Mahdi OS, Jennings R, Mbena E, Mabey
DC. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha
(TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun
1997;65:1003-1006.
343. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the
NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998;338:640644.
344. Thomas HC, Foster GR, Sumiya M, McIntosh D, Jack DL, Turner MW, Summerfield JA.
Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection.
Lancet 1996;348:1417-1419.
345. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, Rittner C. A
tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic
hepatitis B infection. Clin Exp Immunol 1998;111:579-582.
346. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, Trent RJ. Elite endurance
athletes and the ACE I allele--the role of genes in athletic performance. Hum Genet
1998;103:48-50.
347. Rothman N, Smith MT, Hayes RB, Traver RD, Hoener B, Campleman S, Li GL, Dosemeci M,
Linet M, Zhang L, Xi L, Wacholder S, Lu W, Meyer KB, Titenko-Holland N, Stewart JT, Yin S,
Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the
NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res
1997;57:2839-2842.
23
Hirschhorn et al., Comprehensive review of association studies
348. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating
hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet
1995;11:328-330.
349. Morrell NW, Sarybaev AS, Alikhan A, Mirrakhimov MM, Aldashev AA. ACE genotype and
risk of high altitude pulmonary hypertension in Kyrghyz highlanders [letter]. Lancet
1999;353:814.
350. Wetmur JG, Kaya AH, Plewinska M, Desnick RJ. Molecular characterization of the human
delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of
individuals for genetic susceptibility to lead poisoning. Am J Hum Genet 1991;49:757-763.
351. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D.
Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29-32.
352. Merched A, Xia Y, Papadopoulou A, Siest G, Visvikis S. Apolipoprotein AIV codon 360
mutation increases with human aging and is not associated with Alzheimer's disease. Neurosci
Lett 1998;242:117-119.
353. Wick U, Witt E, Engel W. Restriction fragment length polymorphisms at the apoprotein genes
AI, CIII and B-100 and in the 5' flanking region of the insulin gene as possible markers of
coronary heart disease. Clin Genet 1995;47:184-190.
354. Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglund L. Apolipoprotein E polymorphism
in a healthy Swedish population: variation of allele frequency with age and relation to serum
lipid concentrations. Clin Chem 1993;39:2125-2129.
355. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, Taioli E, Sansoni P,
Bertolini S, Franceschi C. Gene polymorphisms predicting high plasma levels of coagulation and
fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol 1997;17:755-759.
356. Klaver CC, Kliffen M, van Duijn CM, Hofman A, Cruts M, Grobbee DE, van Broeckhoven C,
de Jong PT. Genetic association of apolipoprotein E with age-related macular degeneration
[published erratum appears in Am J Hum Genet 1998 Oct;63(4):1252]. Am J Hum Genet
1998;63:200-206.
357. Kimura K, Isashiki Y, Sonoda S, Kakiuchi-Matsumoto T, Ohba N. Genetic association of
manganese superoxide dismutase with exudative age-related macular degeneration. Am J
Ophthalmol 2000;130:769-773.
358. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The
dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics
1996;6:73-79.
359. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S, Sirota LA, Marcus SE,
Greenberg BD, Lucas FRt, Benjamin J, Murphy DL, Hamer DH. A genetic association for
cigarette smoking behavior [comment]. Health Psychol 1999;18:7-13.
360. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM. Influence of polymorphisms
of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational
exposure to trichloroethene. Arch Toxicol 1997;71:596-599.
361. Stein J, Mulliken JB, Stal S, Gasser DL, Malcolm S, Winter R, Blanton SH, Amos C,
Seemanova E, Hecht JT. Nonsyndromic cleft lip with or without cleft palate: evidence of linkage
to BCL3 in 17 multigenerational families [published erratum appears in Am J Hum Genet 1996
Sep;59(3):744]. Am J Hum Genet 1995;57:257-272.
362. Lidral AC, Romitti PA, Basart AM, Doetschman T, Leysens NJ, Daack-Hirsch S, Semina EV,
Johnson LR, Machida J, Burds A, Parnell TJ, Rubenstein JL, Murray JC. Association of MSX1
and TGFB3 with nonsyndromic clefting in humans. Am J Hum Genet 1998;63:557-568.
24
Hirschhorn et al., Comprehensive review of association studies
363. Chenevix-Trench G, Jones K, Green AC, Duffy DL, Martin NG. Cleft lip with or without cleft
palate: associations with transforming growth factor alpha and retinoic acid receptor loci. Am J
Hum Genet 1992;51:1377-1385.
364. Ardinger HH, Buetow KH, Bell GI, Bardach J, VanDemark DR, Murray JC. Association of
genetic variation of the transforming growth factor-alpha gene with cleft lip and palate. Am J
Hum Genet 1989;45:348-353.
365. Tanabe A, Taketani S, Endo-Ichikawa Y, Tokunaga R, Ogawa Y, Hiramoto M. Analysis of the
candidate genes responsible for non-syndromic cleft lip and palate in Japanese people. Clin Sci
(Colch) 2000;99:105-111.
366. Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, Platt R, Gilfix BM, Rosenblatt DS,
Gravel RA, Forbes P, Rozen R. Genetic polymorphisms in methylenetetrahydrofolate reductase
and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J
Med Genet 1999;84:151-157.
367. Morrison K, Papapetrou C, Attwood J, Hol F, Lynch SA, Sampath A, Hamel B, Burn J,
Sowden J, Stott D, Mariman E, Edwards YH. Genetic mapping of the human homologue (T) of
mouse T(Brachyury) and a search for allele association between human T and spina bifida. Hum
Mol Genet 1996;5:669-674.
368. Chung E, Curtis D, Chen G, Marsden PA, Twells R, Xu W, Gardiner M. Genetic evidence for
the neuronal nitric oxide synthase gene (NOS1) as a susceptibility locus for infantile pyloric
stenosis. Am J Hum Genet 1996;58:363-370.
369. Ramet M, Haataja R, Marttila R, Floros J, Hallman M. Association between the surfactant
protein A (SP-A) gene locus and respiratory-distress syndrome in the Finnish population. Am J
Hum Genet 2000;66:1569-1579.
370. Weber B, Borkhardt A, Stoll-Becker S, Reiss I, Gortner L. Polymorphisms of surfactant protein
A genes and the risk of bronchopulmonary dysplasia in preterm infants. Turk J Pediatr
2000;42:181-185.
371. Feucht M, Fuchs K, Pichlbauer E, Hornik K, Scharfetter J, Goessler R, Fureder T, Cvetkovic N,
Sieghart W, Kasper S, Aschauer H. Possible association between childhood absence epilepsy and
the gene encoding GABRB3. Biol Psychiatry 1999;46:997-1002.
372. Sander T, Berlin W, Gscheidel N, Wendel B, Janz D, Hoehe MR. Genetic variation of the
human mu-opioid receptor and susceptibility to idiopathic absence epilepsy. Epilepsy Res
2000;39:57-61.
373. Sander T, Berlin W, Ostapowicz A, Samochowiec J, Gscheidel N, Hoehe MR. Variation of the
genes encoding the human glutamate EAAT2, serotonin and dopamine transporters and
susceptibility to idiopathic generalized epilepsy. Epilepsy Res 2000;41:75-81.
374. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B, Jr.,
Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is
genetically associated with Alzheimer disease. Nat Genet 1998;19:357-360.
375. Liao A, Nitsch RM, Greenberg SM, Finckh U, Blacker D, Albert M, Rebeck GW, Gomez-Isla
T, Clatworthy A, Binetti G, Hock C, Mueller-Thomsen T, Mann U, Zuchowski K, Beisiegel U,
Staehelin H, Growdon JH, Tanzi RE, Hyman BT. Genetic association of an alpha2macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet
1998;7:1953-1956.
376. Hu J, Miyatake F, Aizu Y, Nakagawa H, Nakamura S, Tamaoka A, Takahash R, Urakami K,
Shoji M. Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the
Japanese population. Neurosci Lett 1999;277:65-67.
25
Hirschhorn et al., Comprehensive review of association studies
377. Hu Q, Kukull WA, Bressler SL, Gray MD, Cam JA, Larson EB, Martin GM, Deeb SS. The
human FE65 gene: genomic structure and an intronic biallelic polymorphism associated with
sporadic dementia of the Alzheimer type. Hum Genet 1998;103:295-303.
378. Csaszar A, Kalman J, Szalai C, Janka Z, Romics L. Association of the apolipoprotein A-IV
codon 360 mutation in patients with Alzheimer's disease. Neurosci Lett 1997;230:151-154.
379. Kamino K, Yoshiiwa A, Nishiwaki Y, Nagano K, Yamamoto H, Kobayashi T, Nonomura Y,
Yoneda H, Sakai T, Imagawa M, Miki T, Ogihara T. Genetic association study between senile
dementia of Alzheimer's type and APOE/C1/C2 gene cluster. Gerontology 1996;42 Suppl 1:1219.
380. Schellenberg GD, Deeb SS, Boehnke M, Bryant EM, Martin GM, Lampe TH, Bird TD.
Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type. J
Neurogenet 1987;4:97-108.
381. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E
polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.
382. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K
variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet
1997;6:1933-1936.
383. Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, Ferrell RE. Bleomycin hydrolase
is associated with risk of sporadic Alzheimer's disease [letter] [published erratum appears in Nat
Genet 1998 Aug;19(4):404]. Nat Genet 1998;18:211-212.
384. Papassotiropoulos A, Bagli M, Feder O, Jessen F, Maier W, Rao ML, Ludwig M, Schwab SG,
Heun R. Genetic polymorphism of cathepsin D is strongly associated with the risk for
developing sporadic Alzheimer's disease. Neurosci Lett 1999;262:171-174.
385. Tsai SJ, Liu HC, Liu TY, Wang YC, Hong CJ. Association analysis of the 5-HT6 receptor
polymorphism C267T in Alzheimer's disease. Neurosci Lett 1999;276:138-139.
386. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS,
Dewar D, Love S, Moss T, Griffin WS. Association of interleukin-1 gene polymorphisms with
Alzheimer's disease. Ann Neurol 2000;47:365-368.
387. Wavrant-DeVrieze F, Perez-Tur J, Lambert JC, Frigard B, Pasquier F, Delacourte A, Amouyel
P, Hardy J, Chartier-Harlin MC. Association between the low density lipoprotein receptorrelated protein (LRP) and Alzheimer's disease. Neurosci Lett 1997;227:68-70.
388. Dahiyat M, Cumming A, Harrington C, Wischik C, Xuereb J, Corrigan F, Breen G, Shaw D, St
Clair D. Association between Alzheimer's disease and the NOS3 gene. Ann Neurol 1999;46:664667.
389. Wragg M, Hutton M, Talbot C. Genetic association between intronic polymorphism in
presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group.
Lancet 1996;347:509-512.
390. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE*4-associated Alzheimer's disease
risk is modified by alpha 1-antichymotrypsin polymorphism. Nat Genet 1995;10:486-488.
391. Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, Lesch KP, Powell J, Lovestone S,
Collier D. Allelic functional variation of serotonin transporter expression is a susceptibility
factor for late onset Alzheimer's disease. Neuroreport 1997;8:683-686.
392. van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ. Increased frequency of
the transferrin C2 subtype in Alzheimer's disease. Neuroreport 1993;4:1269-1271.
393. Lambert JC, Goumidi L, Vrieze FW, Frigard B, Harris JM, Cummings A, Coates J, Pasquier F,
Cottel D, Gaillac M, St Clair D, Mann DM, Hardy J, Lendon CL, Amouyel P, Chartier-Harlin
26
Hirschhorn et al., Comprehensive review of association studies
MC. The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic
determinant of Alzheimer's disease. Hum Mol Genet 2000;9:2275-2280.
394. Luedecking EK, DeKosky ST, Mehdi H, Ganguli M, Kamboh MI. Analysis of genetic
polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease.
Hum Genet 2000;106:565-569.
395. Feuk L, Prince JA, Breen G, Emahazion T, Carothers A, St Clair D, Brookes AJ.
apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding
of a positive association for a polymorphism in the TNFRSF6 gene. Hum Genet 2000;107:391396.
396. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka
H, Takahashi H, et al. Genetic association of the very low density lipoprotein (VLDL) receptor
gene with sporadic Alzheimer's disease. Nat Genet 1995;11:207-209.
397. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype
predisposes to sporadic Creutzfeldt-Jakob disease [published erratum appears in Nature 1991
Aug 8;352(6335):547]. Nature 1991;352:340-342.
398. Steinlein O, Sander T, Stoodt J, Kretz R, Janz D, Propping P. Possible association of a silent
polymorphism in the neuronal nicotinic acetylcholine receptor subunit alpha4 with common
idiopathic generalized epilepsies. Am J Med Genet 1997;74:445-449.
399. Ma JJ, Nishimura M, Mine H, Kuroki S, Nukina M, Ohta M, Saji H, Obayashi H, Kawakami H,
Saida T, Uchiyama T. Genetic contribution of the tumor necrosis factor region in Guillain-Barre
syndrome. Ann Neurol 1998;44:815-818.
400. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism
with outcome after head injury. Lancet 1997;350:1069-1071.
401. Nacmias B, Tedde A, Guarnieri BM, Petruzzi C, Ortenzi L, Serio A, Amaducci L, Sorbi S.
Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in
dementia caused by normal pressure hydrocephalus in man. Neurosci Lett 1997;229:177-180.
402. Takenaka K, Yamakawa H, Sakai H, Yoshimura S, Murase S, Okumura A, Nakatani K, Kimura
T, Nishimura Y, Yoshimi N, Sakai N. Angiotensin I-converting enzyme gene polymorphism in
intracranial saccular aneurysm individuals. Neurol Res 1998;20:607-611.
403. Takenaka K, Sakai H, Yamakawa H, Yoshimura S, Kumagai M, Nakashima S, Nozawa Y,
Sakai N. Polymorphism of the endoglin gene in patients with intracranial saccular aneurysms. J
Neurosurg 1999;90:935-938.
404. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE. Functional polymorphism in the matrix
metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke
1999;30:2612-2616.
405. Markus HS, Barley J, Lunt R, Bland JM, Jeffery S, Carter ND, Brown MM. Angiotensinconverting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not
carotid atheroma. Stroke 1995;26:1329-1333.
406. Ji Y, Urakami K, Adachi Y, Maeda M, Isoe K, Nakashima K. Apolipoprotein E polymorphism
in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease.
Dement Geriatr Cogn Disord 1998;9:243-245.
407. Ito D, Murata M, Watanabe K, Yoshida T, Saito I, Tanahashi N, Fukuuchi Y. C242T
polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the
Japanese population. Stroke 2000;31:936-939.
27
Hirschhorn et al., Comprehensive review of association studies
408. Alberts MJ, Davis JP, Graffagnino C, McClenny C, Delong D, Granger C, Herbstreith MH,
Boteva K, Marchuk DA, Roses AD. Endoglin gene polymorphism as a risk factor for sporadic
intracerebral hemorrhage. Ann Neurol 1997;41:683-686.
409. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: a
novel association with primary intracerebral hemorrhage. Stroke 1998;29:813-816.
410. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali
PA, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular
ischemic disease in young patients. Blood 1998;91:3562-3565.
411. Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo T, Ikeda U, Shimada K,
Matsuo M. Genetic variation in the promoter region of the beta-fibrinogen gene is associated
with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 1998;9:373-379.
412. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT, Jr., Pearce RM, Rosendaal FR, Psaty
BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young
women. Stroke 2000;31:1628-1633.
413. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y,
Kitamura K, Yazaki Y. Methylenetetrahydrofolate reductase gene polymorphism and ischemic
stroke in Japanese. Arterioscler Thromb Vasc Biol 1998;18:1465-1469.
414. Soriente L, Coppola A, Madonna P, Cerbone AM, Di Minno G, Orefice G, D'Angelo A.
Homozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and
hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke
1998;29:869-871.
415. Elbaz A, Poirier O, Moulin T, Chedru F, Cambien F, Amarenco P. Association between the
Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain
infarction. The GENIC Investigators. Stroke 2000;31:1634-1639.
416. Rubattu S, Ridker P, Stampfer MJ, Volpe M, Hennekens CH, Lindpaintner K. The gene
encoding atrial natriuretic peptide and the risk of human stroke. Circulation 1999;100:17221726.
417. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma plateletactivating factor acetylhydrolase (Val279- ->Phe) is a genetic risk factor for stroke. Stroke
1997;28:2417-2420.
418. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo
T, Oh-hashi Y, Yazaki Y. Evidence for association between paraoxonase gene polymorphisms
and atherosclerotic diseases. Atherosclerosis 2000;149:435-442.
419. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR. Evidence for allelic
association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical
migraine. Neurogenetics 2000;3:35-40.
420. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T
mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine.
Am J Med Genet 2000;96:762-764.
421. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ,
Olesen J. Altered allelic distributions of the serotonin transporter gene in migraine without aura
and migraine with aura. Cephalalgia 1998;18:23-26.
422. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple
sclerosis. J Neuroimmunol 1999;97:182-190.
28
Hirschhorn et al., Comprehensive review of association studies
423. Crusius JB, Pena AS, Van Oosten BW, Bioque G, Garcia A, Dijkstra CD, Polman CH.
Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet
1995;346:979.
424. Boylan KB, Takahashi N, Paty DW, Sadovnick AD, Diamond M, Hood LE, Prusiner SB. DNA
length polymorphism 5' to the myelin basic protein gene is associated with multiple sclerosis.
Ann Neurol 1990;27:291-297.
425. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, Wonigeit K, Lindert RB,
Kantarci O, Schaefer-Klein J, Schipper HI, Oertel WH, Heidenreich F, Weinshenker BG,
Sommer N, Hemmer B. A point mutation in PTPRC is associated with the development of
multiple sclerosis. Nat Genet 2000;26:495-499.
426. Raknes G, Skeie GO, Gilhus NE, Aadland S, Vedeler C. FcgammaRIIA and FcgammaRIIIB
polymorphisms in myasthenia gravis. J Neuroimmunol 1998;81:173-176.
427. Huang D, Pirskanen R, Hjelmstrom P, Lefvert AK. Polymorphisms in IL-1beta and IL-1
receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 1998;81:7681.
428. Hjelmstrom P, Peacock CS, Giscombe R, Pirskanen R, Lefvert AK, Blackwell JM, Sanjeevi
CB. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis. J
Neuroimmunol 1998;88:137-143.
429. McKenna MJ, Kristiansen AG, Bartley ML, Rogus JJ, Haines JL. Association of COL1A1 and
otosclerosis: evidence for a shared genetic etiology with mild osteogenesis imperfecta. Am J Otol
1998;19:604-610.
430. Kruger R, Menezes-Saecker AM, Schols L, Kuhn W, Muller T, Woitalla D, Berg D, Berger K,
Przuntek H, Epplen JT, Riess O. Genetic analysis of the alpha2-macroglobulin gene in early- and
late-onset Parkinson's disease. Neuroreport 2000;11:2439-2442.
431. Buervenich S, Sydow O, Carmine A, Zhang Z, Anvret M, Olson L. Alcohol dehydrogenase
alleles in Parkinson's disease. Mov Disord 2000;15:813-818.
432. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K, Ishizuka C, Nakamura T. Association
between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin
Genet 1999;56:394-399.
433. Kunugi H, Vallada HP, Sham PC, Hoda F, Arranz MJ, Li T, Nanko S, Murray RM, McGuffin
P, Owen M, Gill M, Collier DA. Catechol-O-methyltransferase polymorphisms and
schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatr Genet
1997;7:97-101.
434. Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I. Genetic association
between cytochrome P450IA1 gene and susceptibility to Parkinson's disease. J Neural Transm
Gen Sect 1996;103:843-849.
435. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine
hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
436. Kobayashi T, Matsumine H, Matuda S, Mizuno Y. Association between the gene encoding the
E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann
Neurol 1998;43:120-123.
437. Plante-Bordeneuve V, Taussig D, Thomas F, Said G, Wood NW, Marsden CD, Harding AE.
Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and
sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology
1997;48:1589-1593.
29
Hirschhorn et al., Comprehensive review of association studies
438. Ahmadi A, Fredrikson M, Jerregard H, Akerback A, Fall PA, Rannug A, Axelson O, Soderkvist
P. GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochem
Biophys Res Commun 2000;269:676-680.
439. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease,
pesticides, and glutathione transferase polymorphisms. Lancet 1998;352:1344-1346.
440. Nakatome M, Tun Z, Shimada S, Honda K. Detection and analysis of four polymorphic
markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with
Parkinson's disease. Biochem Biophys Res Commun 1998;247:452-456.
441. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B
allele with Parkinson's disease. Ann Neurol 1993;33:368-372.
442. Pastor P, Ezquerra M, Munoz E, Marti MJ, Blesa R, Tolosa E, Oliva R. Significant association
between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol 2000;47:242-245.
443. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. Association of slow acetylator
genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997;350:11361139.
444. Sohn YK, Ganju N, Bloch KD, Wands JR, de la Monte SM. Neuritic sprouting with aberrant
expression of the nitric oxide synthase III gene in neurodegenerative diseases. J Neurol Sci
1999;162:133-151.
445. Yamamoto M, Kondo I, Ogawa N, Asanuma M, Yamashita Y, Mizuno Y. Genetic association
between susceptibility to Parkinson's disease and alpha1-antichymotrypsin polymorphism. Brain
Res 1997;759:153-155.
446. Le Couteur DG, Leighton PW, McCann SJ, Pond S. Association of a polymorphism in the
dopamine-transporter gene with Parkinson's disease. Mov Disord 1997;12:760-763.
447. McCann SJ, McManus ME, Johnson AG, Mellick GD, Le Couteur DG, Pond SM. The
serotonin transporter gene and Parkinson's disease. Eur Neurol 2000;44:108-111.
448. Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of
NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology
2000;54:1195-1198.
449. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control
study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology
1999;53:1858-1860.
450. Georgiou I, Syrrou M, Bouba I, Dalkalitsis N, Paschopoulos M, Navrozoglou I, Lolis D.
Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril
1999;72:164-166.
451. Gloria-Bottini F, Nicotra M, Lucarini N, Borgiani P, La Torre M, Amante A, Gimelfarb A,
Bottini E. Phosphotyrosine-protein-phosphatases and human reproduction: an association
between low molecular weight acid phosphatase (ACP1) and spontaneous abortion. Dis Markers
1996;12:261-269.
452. Tsai AF, Kaufman KA, Walker MA, Karrison TG, Odem RR, Barnes RB, Scott JR, Schreiber
JR, Stephenson MD, Ober C. Transmission disequilibrium of maternally-inherited CTLA-4
microsatellite alleles in idiopathic recurrent miscarriage. J Reprod Immunol 1998;40:147-157.
453. Wang X, Wang M, Niu T, Chen C, Xu X. Microsomal epoxide hydrolase polymorphism and
risk of spontaneous abortion. Epidemiology 1998;9:540-544.
454. Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A, Agorastos T, Zournatzi V,
Makris PE, Bontis J, Kotsis A. Factor V leiden and prothrombin G20210A mutations, but not
30
Hirschhorn et al., Comprehensive review of association studies
methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum
Reprod 2000;15:458-462.
455. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, Scianname
N, Pavone G, Di Minno G. Factor V Leiden is associated with repeated and recurrent
unexplained fetal losses. Thromb Haemost 1997;77:822-824.
456. Lissak A, Sharon A, Fruchter O, Kassel A, Sanderovitz J, Abramovici H. Polymorphism for
mutation of cytosine to thymine at location 677 in the methylenetetrahydrofolate reductase gene
is associated with recurrent early fetal loss. Am J Obstet Gynecol 1999;181:126-130.
457. Morgan L, Crawshaw S, Baker PN, Brookfield JF, Broughton Pipkin F, Kalsheker N.
Distortion of maternal-fetal angiotensin II type 1 receptor allele transmission in pre-eclampsia. J
Med Genet 1998;35:632-636.
458. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB.
Increased frequency of genetic thrombophilia in women with complications of pregnancy. N
Engl J Med 1999;340:9-13.
459. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may
predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-905.
460. Hubel CA, Roberts JM, Ferrell RE. Association of pre-eclampsia with common coding
sequence variations in the lipoprotein lipase gene. Clin Genet 1999;56:289-296.
461. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate
reductase polymorphism and pre-eclampsia. J Med Genet 1997;34:525-526.
462. Arngrimsson R, Hayward C, Nadaud S, Baldursdottir A, Walker JJ, Liston WA, Bjarnadottir
RI, Brock DJ, Geirsson RT, Connor JM, Soubrier F. Evidence for a familial pregnancy-induced
hypertension locus in the eNOS-gene region. Am J Hum Genet 1997;61:354-362.
463. Yamada N, Arinami T, Yamakawa-Kobayashi K, Watanabe H, Sohda S, Hamada H, Kubo T,
Hamaguchi H. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is
associated with severe preeclampsia. J Hum Genet 2000;45:138-141.
464. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, McKillop JH. Tumour necrosis factoralpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol
1996;104:154-159.
465. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic
polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without
a history of wheezing. J Clin Invest 1997;100:3184-3188.
466. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R,
Bondy B. Evidence for an association between a G-protein beta3-gene variant with depression
and response to antidepressant treatment. Neuroreport 2000;11:1893-1897.
467. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PlA2
polymorphism and efficacy of aspirin [letter]. Lancet 1998;351:1253.
468. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES,
Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from
azathioprine. Ann Intern Med 1998;129:716-718.
469. Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, Smith I, Gill M, Kerwin RW.
Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and
schizophrenia. Hum Genet 1996;97:714-719.
470. Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ. The
major histocompatibility complex region marked by HSP70-1 and HSP70- 2 variants is
31
Hirschhorn et al., Comprehensive review of association studies
associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood
1995;86:3835-3840.
471. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association
between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet
1995;346:281-282.
472. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin
RW. Association between clozapine response and allelic variation in the 5- HT2C receptor gene.
Neuroreport 1995;7:169-172.
473. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ. Serotonin-6 receptor variant (C267T)
and clinical response to clozapine. Neuroreport 1999;10:1231-1233.
474. Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, Yunis EJ. Tumor necrosis
factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic
groups. Blood 1997;89:4167-4174.
475. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer
HN, Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive. Schizophr
Res 1998;32:101-106.
476. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K. Tardive dyskinesia and
debrisoquine 4-hydroxylase (CYP2D6) genotype in. Schizophr Res 1998;32:107-113.
477. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2
receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827-829.
478. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and
susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-145.
479. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir
A, Lerner A, Goltser T, Shelevoy A, Lerer B. Association between the serotonin 2C receptor
gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and
DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000;152:408-413.
480. Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, Nakamura J. Manganese
superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia.
Neuropsychopharmacology 2000;23:170-177.
481. Guzman EC, Hirata MH, Quintao EC, Hirata RD. Association of the apolipoprotein B gene
polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with
high risk for coronary heart disease. Clin Chem Lab Med 2000;38:731-736.
482. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the
promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol
Psychiatry 1998;3:508-511.
483. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K,
Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan. Cancer Res
2000;60:6921-6926.
484. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N,
Silverman ES, Katz DA, Drajesk J. Pharmacogenetic association between ALOX5 promoter
genotype and the response to anti-asthma treatment [In Process Citation]. Nat Genet
1999;22:168-170.
485. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic
inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of
lithium-responsive manic-depressive illness. Pharmacogenetics 1998;8:259-268.
32
Hirschhorn et al., Comprehensive review of association studies
486. Schulz WA, Krummeck A, Rosinger I, Schmitz-Drager BJ, Sies H. Predisposition towards
urolithiasis associated with the NQO1 null-allele. Pharmacogenetics 1998;8:453-454.
487. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T,
Ishizaki T, Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for
Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-1030.
488. Sagar M, Seensalu R, Tybring G, Dahl ML, Bertilsson L. CYP2C19 genotype and phenotype
determined with omeprazole in patients with acid-related disorders with and without
Helicobacter pylori infection. Scand J Gastroenterol 1998;33:1034-1038.
489. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie
KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in
the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study
Group. N Engl J Med 1998;338:86-93.
490. de Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, Kastelein JJ,
van Boven AJ, Bruschke AV, Humphries SE, Kluft C, Henney AM. Effect of the stromelysin-1
promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol
1999;83:852-856.
491. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu
J, Gilfix BM, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment
outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260-12264.
492. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays
LR, Wedlund PJ. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs
and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-534.
493. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome
P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet
1999;353:717-719.
494. Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J. Association between 5-HT2A
gene promoter polymorphism and anorexia nervosa [letter]. Lancet 1997;350:412.
495. Eisenberg J, Mei-Tal G, Steinberg A, Tartakovsky E, Zohar A, Gritsenko I, Nemanov L,
Ebstein RP. Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention
deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with
ADHD impulsive-hyperactive phenotype. Am J Med Genet 1999;88:497-502.
496. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, Kennedy JL. Dopamine D4
receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol
Psychiatry 1996;1:121-124.
497. Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptibility loci in attention deficit
hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to
affected children. Mol Psychiatry 1999;4:192-196.
498. Cook EH, Jr., Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL.
Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet
1995;56:993-998.
499. Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, Basile VS, Beitchman J,
Kennedy JL. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in
attention deficit hyperactivity disorder (ADHD). Mol Psychiatry 2000;5:537-541.
500. Barr CL, Feng Y, Wigg K, Bloom S, Roberts W, Malone M, Schachar R, Tannock R, Kennedy
JL. Identification of DNA variants in the SNAP-25 gene and linkage study of these
polymorphisms and attention-deficit hyperactivity disorder. Mol Psychiatry 2000;5:405-409.
33
Hirschhorn et al., Comprehensive review of association studies
501. Persico AM, Militerni R, Bravaccio C, Schneider C, Melmed R, Trillo S, Montecchi F, Palermo
MT, Pascucci T, Puglisi-Allegra S, Reichelt KL, Conciatori M, Baldi A, Keller F. Adenosine
deaminase alleles and autistic disorder: case-control and family-based association studies. Am J
Med Genet 2000;96:784-790.
502. Petit E, Herault J, Martineau J, Perrot A, Barthelemy C, Hameury L, Sauvage D, Lelord G,
Muh JP. Association study with two markers of a human homeogene in infantile autism. J Med
Genet 1995;32:269-274.
503. Vincent JB, Konecki DS, Munstermann E, Bolton P, Poustka A, Poustka F, Gurling HM. Point
mutation analysis of the FMR-1 gene in autism. Mol Psychiatry 1996;1:227-231.
504. Bellivier F, Laplanche JL, Schurhoff F, Feingold J, Feline A, Jouvent R, Launay JM, Leboyer
M. Apolipoprotein E gene polymorphism in early and late onset bipolar patients. Neurosci Lett
1997;233:45-48.
505. Mynett-Johnson L, Murphy V, McCormack J, Shields DC, Claffey E, Manley P, McKeon P.
Evidence for an allelic association between bipolar disorder and a Na+, K+ adenosine
triphosphatase alpha subunit gene (ATP1A3). Biol Psychiatry 1998;44:47-51.
506. Li T, Vallada H, Curtis D, Arranz M, Xu K, Cai G, Deng H, Liu J, Murray R, Liu X, Collier
DA. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han
Chinese subjects and allelic association of the low activity allele with bipolar affective disorder.
Pharmacogenetics 1997;7:349-353.
507. Borglum AD, Bruun TG, Kjeldsen TE, Ewald H, Mors O, Kirov G, Russ C, Freeman B, Collier
DA, Kruse TA. Two novel variants in the DOPA decarboxylase gene: association with bipolar
affective disorder. Mol Psychiatry 1999;4:545-551.
508. Parsian A, Chakraverty S, Todd RD. Possible association between the dopamine D3 receptor
gene and bipolar affective disorder. Am J Med Genet 1995;60:234-237.
509. Papadimitriou GN, Dikeos DG, Karadima G, Avramopoulos D, Daskalopoulou EG,
Vassilopoulos D, Stefanis CN. Association between the GABA(A) receptor alpha5 subunit gene
locus (GABRA5) and bipolar affective disorder. Am J Med Genet 1998;81:73-80.
510. Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA. Association analysis of
the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport
2000;11:2017-2020.
511. Vogt IR, Shimron-Abarbanell D, Neidt H, Erdmann J, Cichon S, Schulze TG, Muller DJ, Maier
W, Albus M, Borrmann-Hassenbach M, Knapp M, Rietschel M, Propping P, Nothen MM.
Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and
schizophrenia. Am J Med Genet 2000;96:217-221.
512. Lim LC, Powell J, Sham P, Castle D, Hunt N, Murray R, Gill M. Evidence for a genetic
association between alleles of monoamine oxidase A gene and bipolar affective disorder. Am J
Med Genet 1995;60:325-331.
513. Parsian A, Todd RD. Genetic association between monoamine oxidase and manic-depressive
illness: comparison of relative risk and haplotype relative risk data. Am J Med Genet
1997;74:475-479.
514. Dawson E, Gill M, Curtis D, Castle D, Hunt N, Murray R, Powell J. Genetic association
between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder. Psychiatr
Genet 1995;5:177-180.
515. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, MullerOerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson
A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann
34
Hirschhorn et al., Comprehensive review of association studies
C, Thau K, Rouleau GA, Alda M. Evidence for a role of phospholipase C-gamma1 in the
pathogenesis of bipolar disorder. Mol Psychiatry 1998;3:534-538.
516. Meira-Lima IV, Pereira AC, Mota GF, Krieger JE, Vallada H. Angiotensinogen and
angiotensin converting enzyme gene polymorphisms and the risk of bipolar affective disorder in
humans. Neurosci Lett 2000;293:103-106.
517. Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P, Aitchison KJ, Sodhi M, Li T,
Roberts GW, Smith B, Morton J, Murray RM, Smith D, Kirov G. The serotonin transporter is a
potential susceptibility factor for bipolar affective disorder. Neuroreport 1996;7:1675-1679.
518. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, Allilaire JF, Feingold J,
Mallet J, Malafosse A. Association between the tryptophan hydroxylase gene and manicdepressive illness. Arch Gen Psychiatry 1998;55:33-37.
519. Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C, Dietz G, Gade R. A
study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics
1996;6:223-234.
520. Perez de Castro I, Ibanez A, Torres P, Saiz-Ruiz J, Fernandez-Piqueras J. Genetic association
study between pathological gambling and a functional DNA polymorphism at the D4 receptor
gene. Pharmacogenetics 1997;7:345-348.
521. Arinami T, Li L, Mitsushio H, Itokawa M, Hamaguchi H, Toru M. An insertion/deletion
polymorphism in the angiotensin converting enzyme gene is associated with both brain substance
P contents and affective disorders. Biol Psychiatry 1996;40:1122-1127.
522. Ohara K, Nagai M, Suzuki Y. Low activity allele of catechol-o-methyltransferase gene and
Japanese unipolar depression. Neuroreport 1998;9:1305-1308.
523. Dikeos DG, Papadimitriou GN, Avramopoulos D, Karadima G, Daskalopoulou EG, Souery D,
Mendlewicz J, Vassilopoulos D, Stefanis CN. Association between the dopamine D3 receptor
gene locus (DRD3) and unipolar affective disorder. Psychiatr Genet 1999;9:189-195.
524. Manki H, Kanba S, Muramatsu T, Higuchi S, Suzuki E, Matsushita S, Ono Y, Chiba H,
Shintani F, Nakamura M, Yagi G, Asai M. Dopamine D2, D3 and D4 receptor and transporter
gene polymorphisms and mood disorders. J Affect Disord 1996;40:7-13.
525. Battersby S, Ogilvie AD, Smith CA, Blackwood DH, Muir WJ, Quinn JP, Fink G, Goodwin
GM, Harmar AJ. Structure of a variable number tandem repeat of the serotonin transporter.
Psychiatr Genet 1996;6:177-181.
526. Nielsen DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, Goldman D,
Linnoila M. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen
Psychiatry 1998;55:593-602.
527. Billett EA, Richter MA, Sam F, Swinson RP, Dai XY, King N, Badri F, Sasaki T, Buchanan
JA, Kennedy JL. Investigation of dopamine system genes in obsessive-compulsive disorder.
Psychiatr Genet 1998;8:163-169.
528. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL. Is the 5-HT(1Dbeta) receptor gene
implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry
2000;157:1160-1161.
529. Enoch MA, Kaye WH, Rotondo A, Greenberg BD, Murphy DL, Goldman D. 5-HT2A
promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder
[letter]. Lancet 1998;351:1785-1786.
530. McDougle CJ, Epperson CN, Price LH, Gelernter J. Evidence for linkage disequilibrium
between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol
Psychiatry 1998;3:270-273.
35
Hirschhorn et al., Comprehensive review of association studies
531. Deckert J, Nothen MM, Franke P, Delmo C, Fritze J, Knapp M, Maier W, Beckmann H,
Propping P. Systematic mutation screening and association study of the A1 and A2a adenosine
receptor genes in panic disorder suggest a contribution of the A2a gene to the development of
disease. Mol Psychiatry 1998;3:81-85.
532. Wang Z, Valdes J, Noyes R, Zoega T, Crowe RR. Possible association of a cholecystokinin
promotor polymorphism (CCK- 36CT) with panic disorder. Am J Med Genet 1998;81:228-234.
533. Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM. Apolipoprotein E type epsilon
4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 1995;202:101-104.
534. Tachikawa H, Harada S, Kawanishi Y, Okubo T, Shiraishi H. Novel polymorphisms of the
human cholecystokinin A receptor gene: an association analysis with schizophrenia. Am J Med
Genet 2000;96:141-145.
535. Tachikawa H, Harada S, Kawanishi Y, Okubo T, Shiraishi H. Novel polymorphism in the
promoter and coding regions of the human cholecystokinin B receptor gene: an association
analysis with schizophrenia. Am J Med Genet 1999;88:700-704.
536. Li T, Sham PC, Vallada H, Xie T, Tang X, Murray RM, Liu X, Collier DA. Preferential
transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet 1996;6:131133.
537. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region
of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997;6:577582.
538. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L,
Sokoloff P, Schwartz JC, et al. Association between schizophrenia and homozygosity at the
dopamine D3 receptor gene. J Med Genet 1992;29:858-860.
539. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region
of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun
1999;258:292-295.
540. Williams NM, Cardno AG, Murphy KC, Jones LA, Asherson P, McGuffin P, Owen MJ.
Association between schizophrenia and a microsatellite polymorphism at the dopamine D5
receptor gene. Psychiatr Genet 1997;7:83-85.
541. Schwab SG, Hallmayer J, Lerer B, Albus M, Borrmann M, Honig S, Strauss M, Segman R,
Lichtermann D, Knapp M, Trixler M, Maier W, Wildenauer DB. Support for a chromosome 18p
locus conferring susceptibility to functional psychoses in families with schizophrenia, by
association and linkage analysis. Am J Hum Genet 1998;63:1139-1152.
542. Sanders AR, Rincon-Limas DE, Chakraborty R, Grandchamp B, Hamilton JD, Fann WE, Patel
PI. Association between genetic variation at the porphobilinogen deaminase. Schizophr Res
1993;8:211-221.
543. Orange PR, Heath PR, Wright SR, Ramchand CN, Kolkeiwicz L, Pearson RC. Individuals with
schizophrenia have an increased incidence of the H2R649G allele for the histamine H2 receptor
gene. Mol Psychiatry 1996;1:466-469.
544. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, Aschauer H, Nylander PO,
Macciardi F, Owen MJ. Association between schizophrenia and T102C polymorphism of the 5hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of
Schizophrenia (EMASS) Group. Lancet 1996;347:1294-1296.
545. Tsai SJ, Chiu HJ, Wang YC, Hong CJ. Association study of serotonin-6 receptor variant
(C267T) with schizophrenia and aggressive behavior. Neurosci Lett 1999;271:135-137.
36
Hirschhorn et al., Comprehensive review of association studies
546. Bowen T, Guy CA, Craddock N, Cardno AG, Williams NM, Spurlock G, Murphy KC, Jones
LA, Gray M, Sanders RD, McCarthy G, Chandy KG, Fantino E, Kalman K, Gutman GA, Gargus
JJ, Williams J, McGuffin P, Owen MJ, O'Donovan MC. Further support for an association
between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia. Mol Psychiatry
1998;3:266-269.
547. Nanko S, Hattori M, Kuwata S, Sasaki T, Fukuda R, Dai XY, Yamaguchi K, Shibata Y,
Kazamatsuri H. Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta
Psychiatr Scand 1994;89:390-392.
548. Ishiguro H, Ohtsuki T, Toru M, Itokawa M, Aoki J, Shibuya H, Kurumaji A, Okubo Y,
Iwawaki A, Ota K, Shimizu H, Hamaguchi H, Arinami T. Association between polymorphisms
in the type 1 sigma receptor gene and schizophrenia. Neurosci Lett 1998;257:45-48.
549. Hudson CJ, Kennedy JL, Gotowiec A, Lin A, King N, Gojtan K, Macciardi F, Skorecki K,
Meltzer HY, Warsh JJ, Horrobin DF. Genetic variant near cytosolic phospholipase A2 associated
with schizophrenia. Schizophr Res 1996;21:111-116.
550. Bell R, Collier DA, Rice SQ, Roberts GW, MacPhee CH, Kerwin RW, Price J, Gloger IS.
Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis
in schizophrenia. Biochem Biophys Res Commun 1997;241:630-635.
551. Bell R, Munro J, Russ C, Powell JF, Bruinvels A, Kerwin RW, Collier DA. Systematic
screening of the 14-3-3 eta (eta) chain gene for polymorphic variants and case-control analysis in
schizophrenia. Am J Med Genet 2000;96:736-743.
552. Benessiano J, Crestani B, Mestari F, Klouche W, Neukirch F, Hacein-Bey S, Durand G, Aubier
M. High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in
asthma. J Allergy Clin Immunol 1997;99:53-57.
553. Hopes E, McDougall C, Christie G, Dewar J, Wheatley A, Hall IP, Helms PJ. Association of
glutamine 27 polymorphism of beta 2 adrenoceptor with reported childhood asthma: population
based study. BMJ 1998;316:664.
554. Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. Association of CCR5
delta32 with reduced risk of asthma [letter]. Lancet 1999;354:1264-1265.
555. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. DeltaF508 heterozygosity in cystic
fibrosis and susceptibility to asthma [published erratum appears in Lancet 1998 Oct
10;352(9135):1230]. Lancet 1998;351:1911-1913.
556. Fryer AA, Bianco A, Hepple M, Jones PW, Strange RC, Spiteri MA. Polymorphism at the
glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and
asthma. Am J Respir Crit Care Med 2000;161:1437-1442.
557. Yan L, Galinsky RE, Bernstein JA, Liggett SB, Weinshilboum RM. Histamine Nmethyltransferase pharmacogenetics: association of a common functional polymorphism with
asthma. Pharmacogenetics 2000;10:261-266.
558. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associated with low interleukin-10 production
in patients with severe asthma [letter]. Lancet 1998;352:113.
559. van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO,
Bakker A, Verweij CL, Aarden LA, van der Zee JS. An IL-13 promoter polymorphism
associated with increased risk of allergic asthma. Genes Immun 1999;1:61-65.
560. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kawashima T, Yanagi H, Matsui
A, Hamaguchi H. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin
Exp Allergy 1998;28:449-453.
37
Hirschhorn et al., Comprehensive review of association studies
561. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy
with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med
1997;337:1720-1725.
562. Kauppi P, Laitinen T, Ollikainen V, Mannila H, Laitinen LA, Kere J. The IL9R region
contribution in asthma is supported by genetic association in an isolated population. Eur J Hum
Genet 2000;8:788-792.
563. Moffatt MF, Cookson WO. Tumour necrosis factor haplotypes and asthma. Hum Mol Genet
1997;6:551-554.
564. Shirakawa T, Li A, Dubowitz M, Dekker JW, Shaw AE, Faux JA, Ra C, Cookson WO, Hopkin
JM. Association between atopy and variants of the beta subunit of the high-affinity
immunoglobulin E receptor. Nat Genet 1994;7:125-129.
565. Grasemann H, Yandava CN, Drazen JM. Neuronal NO synthase (NOS1) is a major candidate
gene for asthma. Clin Exp Allergy 1999;29 Suppl 4:39-41.
566. Lee YC, Cheon KT, Lee HB, Kim W, Rhee YK, Kim DS. Gene polymorphisms of endothelial
nitric oxide synthase and angiotensin-converting enzyme in patients with asthma. Allergy
2000;55:959-963.
567. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr
J, Hopkin JM, Shirakawa T, Deichmann KA. The Ile198Thr and Ala379Val variants of
plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and
asthma. Am J Hum Genet 2000;66:1522-1530.
568. Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC, Makki R, Tavernier G,
Smilie FI, Custovic A, Woodcock AA, Ollier WE, Hajeer AH. The -403 G-->A promoter
polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun
2000;1:509-514.
569. Holla L, Vasku A, Znojil V, Siskova L, Vacha J. Association of 3 gene polymorphisms with
atopic diseases. J Allergy Clin Immunol 1999;103:702-708.
570. Ismail A, Bousaffara R, Kaziz J, Zili J, el Kamel A, Tahar Sfar M, Remadi S, Chouchane L.
Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians. J
Allergy Clin Immunol 1997;99:216-223.
571. Silvennoinen-Kassinen S, Ikaheimo I, Tiilikainen A. TAP1 and TAP2 genes in nickel allergy.
Int Arch Allergy Immunol 1997;114:94-96.
572. Unoki M, Furuta S, Onouchi Y, Watanabe O, Doi S, Fujiwara H, Miyatake A, Fujita K, Tamari
M, Nakamura Y. Association studies of 33 single nucleotide polymorphisms (SNPs) in 29
candidate genes for bronchial asthma: positive association a T924C polymorphism in the
thromboxane A2 receptor gene. Hum Genet 2000;106:440-446.
573. Laing IA, Goldblatt J, Eber E, Hayden CM, Rye PJ, Gibson NA, Palmer LJ, Burton PR, Le
Souef PN. A polymorphism of the CC16 gene is associated with an increased risk of asthma. J
Med Genet 1998;35:463-467.
574. Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gile LS, Luisetti M, Pignatti PF.
Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum
Genet 1998;103:718-722.
575. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide
hydrolase and susceptibility to emphysema. Lancet 1997;350:630-633.
576. Schellenberg D, Pare PD, Weir TD, Spinelli JJ, Walker BA, Sandford AJ. Vitamin D binding
protein variants and the risk of COPD. Am J Respir Crit Care Med 1998;157:957-961.
38
Hirschhorn et al., Comprehensive review of association studies
577. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi
Y. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive
pulmonary disease. Thorax 1999;54:693-696.
578. Kalsheker NA, Hodgson IJ, Watkins GL, White JP, Morrison HM, Stockley RA.
Deoxyribonucleic acid (DNA) polymorphism of the alpha 1-antitrypsin gene in chronic lung
disease. Br Med J (Clin Res Ed) 1987;294:1511-1514.
579. Ishii T, Matsuse T, Teramoto S, Matsui H, Hosoi T, Fukuchi Y, Ouchi Y. Association between
alpha-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary
disease. Eur J Clin Invest 2000;30:543-548.
580. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic
bronchitis. Am J Respir Crit Care Med 1997;156:1436-1439.
581. Zhai R, Jetten M, Schins RP, Franssen H, Borm PJ. Polymorphisms in the promoter of the
tumor necrosis factor-alpha gene in coal miners. Am J Ind Med 1998;34:318-324.
582. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic
variation in the transforming growth factor-beta1 gene: association with transforming growth
factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation.
Transplantation 1998;66:1014-1020.
583. Carter AM, Catto AJ, Kohler HP, Ariens RA, Stickland MH, Grant PJ. alpha-fibrinogen
Thr312Ala polymorphism and venous thromboembolism. Blood 2000;96:1177-1179.
584. Maliarik MJ, Rybicki BA, Malvitz E, Sheffer RG, Major M, Popovich J, Jr., Iannuzzi MC.
Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit
Care Med 1998;158:1566-1570.
585. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C
chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese
population. Am J Respir Crit Care Med 1999;159:2021-2023.
586. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M, Weigl E, Du Bois R. CC
chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J
Respir Crit Care Med 2000;162:1000-1003.
587. Maliarik MJ, Chen KM, Sheffer RG, Rybicki BA, Major ML, Popovich J, Jr., Iannuzzi MC.
The natural resistance-associated macrophage protein gene in African Americans with
sarcoidosis. Am J Respir Cell Mol Biol 2000;22:672-675.
588. Niimi T, Tomita H, Sato S, Kawaguchi H, Akita K, Maeda H, Sugiura Y, Ueda R. Vitamin D
receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med
1999;160:1107-1109.
589. Li PK, Poon P, Phil M, Poon AS, Szeto CC, Yu AW, Lai KN. Association of IgA nephropathy
with T-cell receptor constant alpha chain gene polymorphism. Am J Kidney Dis 1997;30:260264.
590. Halkas AC, Gaillard MC, Thomson PD, Green SL, Ludewick H, Kala U. Variants of alpha 1proteinase inhibitor in black and white South African patients with focal glomerulosclerosis and
minimal change nephrotic syndrome. J Med Genet 1998;35:6-9.
591. Bachvarov DR, Landry M, Pelletier I, Chevrette M, Betard C, Houde I, Bergeron J, Lebel M,
Marceau F. Characterization of two polymorphic sites in the human kinin B1 receptor gene:
altered frequency of an allele in patients with a history of end-stage renal failure. J Am Soc
Nephrol 1998;9:598-604.
39
Hirschhorn et al., Comprehensive review of association studies
592. Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E. Angiotensin Iconverting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of
chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int 2000;58:513-519.
593. Smolenicka Z, Bach E, Schaer A, Liechti-Gallati S, Frey BM, Frey FJ, Ferrari P. A new
polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene. J
Clin Endocrinol Metab 1998;83:1814-1817.
594. Yu H, Bowden DW, Spray BJ, Rich SS, Freedman BI. Identification of human plasma
kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease.
Hypertension 1998;31:906-911.
595. Wang Y, Kikuchi S, Suzuki H, Nagase S, Koyama A. Endothelial nitric oxide synthase gene
polymorphism in intron 4 affects the progression of renal failure in non-diabetic renal diseases.
Nephrol Dial Transplant 1999;14:2898-2902.
596. Verity DH, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati
CA, Wallace GR, Stanford MR. Intercellular adhesion molecule-1 gene polymorphisms in
Behcet's disease. Eur J Immunogenet 2000;27:73-76.
597. Annunen S, Paassilta P, Lohiniva J, Perala M, Pihlajamaa T, Karppinen J, Tervonen O, Kroger
H, Lahde S, Vanharanta H, Ryhanen L, Goring HH, Ott J, Prockop DJ, Ala-Kokko L. An allele
of COL9A2 associated with intervertebral disc disease. Science 1999;285:409-412.
598. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect
of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6
levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest
1998;102:1369-1376.
599. Donn RP, Davies EJ, Holt PL, Thomson W, Ollier W. Increased frequency of TAP2B in early
onset pauciarticular juvenile chronic arthritis. Ann Rheum Dis 1994;53:261-264.
600. Sanjeevi CB, Miller EN, Dabadghao P, Rumba I, Shtauvere A, Denisova A, Clayton D,
Blackwell JM. Polymorphism at NRAMP1 and D2S1471 loci associated with juvenile
rheumatoid arthritis. Arthritis Rheum 2000;43:1397-1404.
601. Meulenbelt I, Bijkerk C, De Wildt SC, Miedema HS, Breedveld FC, Pols HA, Hofman A, Van
Duijn CM, Slagboom PE. Haplotype analysis of three polymorphisms of the COL2A1 gene and
associations with generalised radiological osteoarthritis. Ann Hum Genet 1999;63:393-400.
602. Keen RW, Hart DJ, Lanchbury JS, Spector TD. Association of early osteoarthritis of the knee
with a Taq I polymorphism of the vitamin D receptor gene. Arthritis Rheum 1997;40:1444-1449.
603. Fife MS, Fisher SA, John S, Worthington J, Shah CJ, Ollier WE, Panayi GS, Lewis CM,
Lanchbury JS. Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis
demonstrates significant evidence of linkage and association with the corticotropin-releasing
hormone genomic region. Arthritis Rheum 2000;43:1673-1678.
604. Baerwald CG, Mok CC, Tickly M, Lau CS, Wordsworth BP, Ollier B, Panayi GS, Lanchbury
JS. Corticotropin releasing hormone (CRH) promoter polymorphisms in various ethnic groups of
patients with rheumatoid arthritis. Z Rheumatol 2000;59:29-34.
605. Takagi H, Ishiguro N, Iwata H, Kanamono T. Genetic association between rheumatoid arthritis
and estrogen receptor microsatellite polymorphism. J Rheumatol 2000;27:1638-1642.
606. Quadri SA, Taneja V, Mehra NK, Singal DP. HSP70-1 promoter region alleles and
susceptibility to rheumatoid arthritis. Clin Exp Rheumatol 1996;14:183-185.
607. Khani-Hanjani A, Lacaille D, Hoar D, Chalmers A, Horsman D, Anderson M, Balshaw R,
Keown PA. Association between dinucleotide repeat in non-coding region of interferon-gamma
gene and susceptibility to, and severity of, rheumatoid arthritis. Lancet 2000;356:820-825.
40
Hirschhorn et al., Comprehensive review of association studies
608. Yang YS, Kim SJ, Kim JW, Koh EM. NRAMP1 gene polymorphisms in patients with
rheumatoid arthritis in Koreans. J Korean Med Sci 2000;15:83-87.
609. Tuokko J, Pushnova E, Yli-Kerttula U, Toivanen A, Ilonen J. TAP2 alleles in inflammatory
arthritis. Scand J Rheumatol 1998;27:225-229.
610. Funkhouser SW, Concannon P, Charmley P, Vredevoe DL, Hood L. Differences in T cell
receptor restriction fragment length polymorphisms in patients with rheumatoid arthritis.
Arthritis Rheum 1992;35:465-471.
611. Morgan AW, Griffiths B, Ponchel F, Montague BM, Ali M, Gardner PP, Gooi HC, Situnayake
RD, Markham AF, Emery P, Isaacs JD. Fcgamma receptor type IIIA is associated with
rheumatoid arthritis in two distinct ethnic groups. Arthritis Rheum 2000;43:2328-2334.
612. Nieto A, Caliz R, Pascual M, Mataran L, Garcia S, Martin J. Involvement of Fcgamma receptor
IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum 2000;43:735-739.
613. Morinobu A, Kanagawa S, Koshiba M, Sugai S, Kumagai S. Association of the glutathione Stransferase M1 homozygous null genotype with susceptibility to Sjogren's syndrome in Japanese
individuals. Arthritis Rheum 1999;42:2612-2615.
614. Tassiulas IO, Aksentijevich I, Salmon JE, Kim Y, Yarboro CH, Vaughan EM, Davis JC, Scott
DL, Austin HA, Klippel JH, Balow JE, Gourley MF, Boumpas DT. Angiotensin I converting
enzyme gene polymorphisms in systemic lupus erythematosus: decreased prevalence of DD
genotype in African American patients. Clin Nephrol 1998;50:8-13.
615. Tsao BP, Cantor RM, Grossman JM, Shen N, Teophilov NT, Wallace DJ, Arnett FC, Hartung
K, Goldstein R, Kalunian KC, Hahn BH, Rotter JI. PARP alleles within the linked chromosomal
region are associated with systemic lupus erythematosus. J Clin Invest 1999;103:1135-1140.
616. Naves M, Hajeer AH, Teh LS, Davies EJ, Ordi-Ros J, Perez-Pemen P, Vilardel-Tarres M,
Thomson W, Worthington J, Ollier WE. Complement C4B null allele status confers risk for
systemic lupus erythematosus in a Spanish population. Eur J Immunogenet 1998;25:317-320.
617. Pullmann R Jr, Lukac J, Skerenova M, Rovensky J, Hybenova J, Melus V, Celec S, Pullmann
R, Hyrdel R. Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic
lupus erythematosus. Clin Exp Rheumatol 1999;17:725-729.
618. Sabbagh N, Marez D, Queyrel V, Lo Guidice JM, Spire C, Vanhille P, Jorgensen C, Hachulla
E, Broly F. Genetic analysis of the cytochrome P450 CYP2D6 polymorphism in patients with
systemic lupus erythematosus. Pharmacogenetics 1998;8:191-194.
619. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman
R, Peterson MG, Kimberly RP. Fc gamma RIIA alleles are heritable risk factors for lupus
nephritis in African Americans. J Clin Invest 1996;97:1348-1354.
620. Jarjour W, Reed AM, Gauthier J, Hunt S 3rd, Winfield JB. The 8.5-kb PstI allele of the stress
protein gene, Hsp70-2: an independent risk factor for systemic lupus erythematosus in African
Americans? Hum Immunol 1996;45:59-63.
621. Huang DF, Siminovitch KA, Liu XY, Olee T, Olsen NJ, Berry C, Carson DA, Chen PP.
Population and family studies of three disease-related polymorphic genes in systemic lupus
erythematosus. J Clin Invest 1995;95:1766-1772.
622. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between
polymorphisms at the human IL-10 locus and systemic lupus erythematosus [published erratum
appears in Tissue Antigens 1997 Dec;50(6):699]. Tissue Antigens 1997;49:635-639.
623. Sullivan KE, Wooten C, Goldman D, Petri M. Mannose-binding protein genetic polymorphisms
in black patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:2046-2051.
41
Hirschhorn et al., Comprehensive review of association studies
624. Fugger L, Morling N, Ryder LP, Georgsen J, Jakobsen BK, Svejgaard A, Andersen V, Oxholm
P, Karup Pedersen F, Friis J, et al. NcoI restriction fragment length polymorphism (RFLP) of the
tumor necrosis factor (TNF alpha) region in four autoimmune diseases. Tissue Antigens
1989;34:17-22.
625. Ozaki Y, Nomura S, Nagahama M, Yoshimura C, Kagawa H, Fukuhara S. Vitamin-D receptor
genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron
2000;85:86-91.
626. Huang D, Giscombe R, Zhou Y, Lefvert AK. Polymorphisms in CTLA-4 but not tumor
necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J
Rheumatol 2000;27:397-401.
627. Gencik M, Meller S, Borgmann S, Fricke H. Proteinase 3 gene polymorphisms and Wegener's
granulomatosis. Kidney Int 2000;58:2473-2477.
628. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and
carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione
S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst
1993;85:1159-1164.
629. Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle JR. Homozygous deletion of gene
for glutathione S-transferase M1 in bladder cancer. BMJ 1993;307:481-482.
630. Inatomi H, Katoh T, Kawamoto T, Matsumoto T. NAT2 gene polymorphism as a possible
marker for susceptibility to bladder cancer in Japanese. Int J Urol 1999;6:446-454.
631. Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1
gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol
1999;35:191-196.
632. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q. Glutathione-S-transferase
polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer
1999;84:220-224.
633. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of
combined genotypes. Jpn J Cancer Res 1992;83:866-870.
634. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically
high risk individuals to lung cancer by DNA. FEBS Lett 1990;263:131-133.
635. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA.
Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.
Cancer Res 1997;57:1194-1198.
636. Genest JJ, Jr., Ordovas JM, McNamara JR, Robbins AM, Meade T, Cohn SD, Salem DN,
Wilson PW, Masharani U, Frossard PM, et al. DNA polymorphisms of the apolipoprotein B gene
in patients with premature coronary artery disease. Atherosclerosis 1990;82:7-17.
637. Saha N, Tong MC, Tay JS, Jeyaseelan K, Humphries SE. DNA polymorphisms of the
apolipoprotein B gene in Chinese coronary artery disease patients. Clin Genet 1992;42:164-170.
638. Ichihara S, Yamada Y, Fujimura T, Nakashima N, Yokota M. Association of a polymorphism
of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the
Japanese population. Am J Cardiol 1998;81:83-86.
639. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'untranslated region of the prothrombin gene is associated with elevated plasma prothrombin
levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
42
Hirschhorn et al., Comprehensive review of association studies
640. Castellano M, Barlassina C, Muiesan ML, Beschi M, Cinelli A, Rossi F, Rizzoni D, Cusi D,
Agabiti-Rosei E. Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general
population. J Hypertens 1997;15:1707-1710.
641. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C,
Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphisms of
alpha-adducin and salt sensitivity in patients with essential hypertension [published erratum
appears in Lancet 1997 Aug 16;350(9076):524]. Lancet 1997;349:1353-1357.
642. Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, Herwig J, Usadel KH,
Badenhoop K. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1
diabetes mellitus. J Clin Endocrinol Metab 1997;82:143-146.
643. Noda K, Matsutani A, Tanizawa Y, Neuman R, Kaneko T, Permutt MA, Kaku K. Polymorphic
microsatellite repeat markers at the glucokinase gene locus are positively associated with
NIDDM in Japanese. Diabetes 1993;42:1147-1152.
644. t Hart LM, Stolk RP, Heine RJ, Grobbee DE, van der Does FE, Maassen JA. Association of the
insulin-receptor variant Met-985 with hyperglycemia and non-insulin-dependent diabetes
mellitus in the Netherlands: a population-based study. Am J Hum Genet 1996;59:1119-1125.
645. Li SR, Baroni MG, Oelbaum RS, Stock J, Galton DJ. Association of genetic variant of the
glucose transporter with non-insulin-dependent diabetes mellitus. Lancet 1988;2:368-370.
646. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD,
Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of
Alzheimer's disease in late onset families. Science 1993;261:921-923.
647. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses
AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4
allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-1981.
648. Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association
between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet
1999;104:158-163.
649. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R.
Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an
apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997;49:56-61.
650. Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AM. Genetic
association studies between dementia of the Alzheimer's type and three receptors for
apolipoprotein E in a Caucasian population. Neurosci Lett 1997;222:187-190.
651. Kehoe P, Williams J, Lovestone S, Wilcock G, Owen MJ. Presenilin-1 polymorphism and
Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group. Lancet 1996;347:1185.
652. Margaglione M, Seripa D, Gravina C, Grandone E, Vecchione G, Cappucci G, Merla G, Papa
S, Postiglione A, Di Minno G, Fazio VM. Prevalence of apolipoprotein E alleles in healthy
subjects and survivors of ischemic stroke: an Italian case-control study. Stroke 1998;29:399-403.
653. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier
DA. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and
possible association with Parkinson's disease. Neurosci Lett 1997;221:202-204.
654. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A,
Badri F, Nothen MM, Kalow W, Kennedy JL. Serotonin subtype 2 receptor genes and clinical
response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19:123-132.
655. Lim LC, Powell JF, Murray R, Gill M. Monoamine oxidase A gene and bipolar affective
disorder. Am J Hum Genet 1994;54:1122-1124.
43
Hirschhorn et al., Comprehensive review of association studies
656. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, Smith CA.
Polymorphism in serotonin transporter gene associated with susceptibility. Lancet 1996;347:731733.
657. Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada
HP, Bengel D, Muller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP. A novel
functional polymorphism within the promoter of the serotonin. Mol Psychiatry 1996;1:453-460.
658. Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong LL, Ho TH, Gutman GA, Crocq MA,
Ganguli R, Nimgaonkar V, Morris-Rosendahl DJ, Gargus JJ. Isolation of a novel potassium
channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and
bipolar disorder?. Mol Psychiatry 1998;3:32-37.
659. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen
K, Shih JC, Knapp M, Propping P, Nothen MM. Systematic screening for mutations in the
human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor
variants and association analysis in schizophrenia. Hum Genet 1996;97:614-619.
660. Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, Takahata R, Koh J, Sakai J,
Takai A, Inada Y, Asaba H. Positive association between a DNA sequence variant in the
serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996;67:103-105.
661. Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake
Y, Hamasaki N, Shirakawa T, Hopkin JM. Ile50Val variant of IL4R alpha upregulates IgE
synthesis and associates with atopic asthma. Nat Genet 1998;19:119-120.
662. Shirakawa T, Mao XQ, Sasaki S, Enomoto T, Kawai M, Morimoto K, Hopkin J. Association
between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population. Hum
Mol Genet 1996;5:1129-1130.
663. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency
of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid
arthritis and systemic lupus erythematosus. Dis Markers 1995;12:127-133.
44
Hirschhorn et al., Comprehensive review of association studies
Supplementary Table 1 (for website)
Number of diseases/traits associated with different genes
Gene # associated diseases/traits
TNF 20
ACE 14
VDR 14
MTHFR 13
GSTM1 11
APOE 10
CTLA4 9
CYP1A1 9
GSTT1 9
CYP2D6 7
DIA4 7
EPHX1 7
GSTP1 7
NAT2 7
NOS3 7
SLC6A4 7
ADRB2 6
COMT 6
DRD2 6
HTR2A 6
LTA 6
SERPINA8 6
TP53 6
APOB 5
DRD3 5
DRD4 5
F2 5
F5 5
SLC11A1 5
TGFB1 5
ALDH2 4
GNB3 4
HRAS 4
HTR6 4
IL10 4
IL1RN 4
MBL2 4
NAT1 4
PLA2G7 4
PPARG 4
SERPINA3 4
45
Hirschhorn et al., Comprehensive review of association studies
SERPINE1 4
SLC6A3 4
SOD2 4
AGTR1 3
C4A 3
CCK 3
CCR2 3
CCR5 3
CDKN1A 3
CYP17 3
CYP1B1 3
CYP2E 3
ESR1 3
F13A1 3
FCGR2A 3
GCK 3
HTR5A 3
ICAM1 3
IFNG 3
INS 3
INSR 3
NPPA 3
PON1 3
TAP1 3
TAP2 3
A2M 2
ABCC8 2
ADRB3 2
APOA1 2
AR 2
BCL2 2
BDKRB1 2
CD4 2
CETP 2
CFTR 2
COL1A1 2
CYBA 2
DRD5 2
ENG 2
ETS1 2
FGB 2
GNAS1 2
GP1BA 2
GYS1 2
HSD11B2 2
HSPA1A 2
46
Hirschhorn et al., Comprehensive review of association studies
HSPA2 2
HSPA8 2
HTR2C 2
IL1B 2
IL4 2
IL6 2
IRS1 2
ITGA2 2
ITGB3 2
LHB 2
LPL 2
MAOA 2
MAOB 2
MC1R 2
MMP3 2
NOS1 2
NOS2A 2
PGR 2
PLAT 2
SERPINA1 2
TF 2
TPH 2
XRCC3 2
ACP1 1
ADA 1
ADD1 1
ADH1B 1
ADH4 1
ADORA2A 1
ADPRT 1
ALAD 1
ALOX5 1
AMPD1 1
APBB1 1
APC 1
APOA4 1
APOC1 1
APOC2 1
APOD 1
ATP1A3 1
BCHE 1
BCL3 1
BLMH 1
C4B 1
CD14 1
CD36 1
47
Hirschhorn et al., Comprehensive review of association studies
CD3D 1
CDSN 1
CHRNA4 1
CMA1 1
COL2A1 1
COL9A2 1
CRH 1
CTSD 1
CX3CR1 1
CYP11A 1
CYP11B2 1
CYP19 1
CYP2A6 1
CYP2C19 1
CYP2C9 1
CYP3A4 1
DBH 1
DCP1 1
DDC 1
DLST 1
DRD1 1
EDNRA 1
ELAC2 1
EN2 1
ERBB2 1
ERCC1 1
F3 1
F7 1
FCGR3A 1
FGA 1
FMR1 1
FRDA 1
FSHB 1
FST 1
GABRA5 1
GABRB3 1
GC 1
GCGR 1
GNAL 1
GPX1 1
GSTM3 1
HFE 1
HMBS 1
HNMT 1
HRH2 1
HTR1B 1
48
Hirschhorn et al., Comprehensive review of association studies
IGHV2-5 1
IGHV3-30-5 1
IL13 1
IL1A 1
IL4R 1
IL9R 1
IMPA1 1
IPF1 1
KCNJ11 1
KCNN3 1
KLKB1 1
LDLR 1
LEP 1
LIPE 1
LRP1 1
MAPT 1
MGMT 1
MLH1 1
MMP1 1
MMP9 1
MPO 1
MS4A1 1
MSH3 1
MSX1 1
MTR 1
MUC1 1
MUC3A 1
MYC 1
MYCL1 1
NEUROD1 1
NMB 1
NPY5R 1
NTF3 1
OPRM1 1
OPRS1 1
OTF3 1
PCSK2 1
PLA2G1B 1
PLA2G4A 1
PLCG1 1
PON2 1
PPP1R3 1
PRNP 1
PRTN3 1
PSEN1 1
PSMB8 1
49
Hirschhorn et al., Comprehensive review of association studies
PTPRC 1
RARA 1
REN 1
RRAD 1
SAH 1
SCNN1B 1
SCYA5 1
SDF1 1
SELE 1
SELP 1
SFTPA1 1
SHBG 1
SLC2A1 1
SLC2A2 1
SNAP25 1
SNCA 1
SRD5A2 1
T1
TBXA2R 1
TCF1 1
TFCP2 1
TGFA 1
TGFB2 1
TGFB3 1
TH 1
THBD 1
THRB 1
TNFRFS6 1
TPMT 1
TRA@ 1
TRD@ 1
TRHR 1
UCHL1 1
UCP3 1
UGB 1
UGT1A1 1
VLDLR 1
WFS1 1
WRN 1
XRCC1 1
YWHAH 1
Gene symbols are as in Table 4. For each gene, the number of entries in Table 1 is shown.
50